cephalotaxu
alkaloid
repres
famili
plant
secondari
metabolit
known
year
signific
activ
leukemia
mice
demonstr
extract
cephalotaxu
cephalotaxin
cet
major
alkaloid
seri
isol
cephalotaxu
drupacea
speci
paudler
subsequ
discoveri
promis
antitumor
activ
among
new
cephalotaxu
deriv
report
chines
japanes
american
team
trigger
extens
structur
elucid
biolog
studi
famili
structur
featur
cephalotaxan
famili
reli
mainli
tetracycl
alkaloid
backbon
compris
azaspiran
nonan
unit
ring
c
benzazepin
ring
system
ring
b
link
alcohol
function
chiral
oxygen
side
chain
carboxyl
function
alpha
tetrasubstitut
carbon
center
botan
distribut
alkaloid
limit
cephalotaxu
genu
cephalotaxacea
scope
biolog
activ
cephalotaxu
alkaloid
mainli
center
antileukem
activ
et
al
homoharringtonin
hht
particular
demonstr
mark
benefit
treatment
orphan
myeloid
leukemia
approv
soon
european
medicin
agenc
us
food
drug
administr
exact
mechan
action
partli
elucid
earli
recogn
hht
inhibit
protein
synthesi
level
ribosom
machineri
interestingli
latenc
period
two
decad
topic
cephalotaxu
alkaloid
reemerg
prolif
sourc
new
natur
structur
date
compound
identifi
character
synthet
studi
also
regain
attent
past
two
decad
numer
methodolog
develop
access
first
semisynthet
hht
high
puriti
suitabl
clinic
studi
high
grade
enantiomer
pure
cet
hht
analog
abbrevi
acac
acetylaceton
ach
acetyl
cholin
esteras
acn
azobi
cyclohexanecarbonitril
adp
adenosin
diphosph
aibn
azobisisobutyronitril
aml
acut
myeloid
leukemia
apl
acut
promyelocyt
leukemia
arac
cytosin
arabinosid
atra
alltransretino
acid
ay
averag
yield
bcrabl
breakpoint
cluster
region
abl
abelson
bid
bi
die
twice
daili
boc
tert
butyloxycarbonyl
bp
blast
phase
brsm
base
recov
start
materi
cbz
carbobenzoxi
ccdc
cambridg
crystallograph
data
center
cdi
carbonyldiimidazol
cet
cephalotaxin
cgaf
cephalotaxu
griffithi
alkaloid
fraction
chr
complet
hematolog
respons
cmc
cell
membran
chromatographi
cml
chronic
myeloid
leukemia
chronic
myelogen
leukemia
cp
chronic
phase
cp
cyclopentadien
csa
camphorsulfon
acid
csd
cambridg
structur
databas
cse
convent
solvent
extract
cta
cephalotaxinamid
dba
dibenzylideneaceton
dbu
dcc
n
n
dicyclohexylcarbodiimid
de
diastereoisomer
excess
depc
diethyl
pyrocarbon
cephalotaxu
alkaloid
khmd
potassium
hexamethyldisilazid
lda
lithium
diisopropylamid
lihmd
lithium
hexamethyldisilazid
lcl
longcircul
liposom
ll
longest
linear
sequenc
loq
limit
quantit
mcpba
metachloroperoxybenzo
acid
myeloid
cell
mcyr
major
cytogenet
respons
et
al
contribut
updat
expand
version
two
preced
chapter
publish
seri
review
focus
structur
synthesi
compound
sever
review
avail
cover
structureeact
relationship
sar
biolog
clinic
properti
alkaloid
literatur
review
last
updat
seri
cover
field
till
earli
usual
exist
form
uniqu
enantiom
number
natur
product
arab
digit
irrespect
optic
rotat
sign
eg
cephalotaxin
cet
antipod
entdigit
eg
entcephalotaxin
ent
correspond
racem
compound
usual
obtain
chemic
synthesi
racdigit
eg
raccephalotaxin
rac
asymmetr
synthesi
section
precis
sign
optic
rotat
eg
cet
entcet
raccet
ae
year
chemist
studi
extract
structur
determin
biogenesi
synthesi
cet
fig
major
alkaloid
seri
relat
alkaloid
report
biolog
activ
natur
ester
view
therapeut
use
treatment
leukemia
homoharringtonin
hht
harringtonin
ht
mixtur
use
tradit
chines
medicin
tcm
sinc
treat
varieti
malign
hht
easiest
purifi
abund
plant
select
nation
cancer
institut
nci
clinic
develop
hht
also
known
omacetaxin
simpl
ester
cet
probabl
hold
record
longest
time
reach
market
experienc
increas
interest
sinc
first
use
tcm
effort
pharmaceut
compani
develop
antileukem
agent
despit
clinic
efficaci
natur
hht
record
simpli
normal
extract
formul
rais
sever
unresolv
problem
reproduct
constant
product
defin
extract
procedur
puriti
profil
main
sourc
raw
materi
china
biodivers
conserv
issu
cephalotaxu
shrub
extrem
slow
growth
mostli
protect
endang
speci
moreov
cet
activ
ester
present
small
quantiti
plant
root
bark
heartwood
leav
hardli
make
possibl
exploit
obtain
hht
relat
ester
semisynthet
hht
sshht
myelostat
ceflatonin
omacetaxin
mepesuccin
om
manufactur
semisynthet
process
develop
robin
natur
occur
alkaloid
cet
extract
dri
leav
cephalotaxu
harringtonia
synthet
precursor
side
chain
although
hht
investig
treatment
chronic
myeloid
leukemia
cml
good
result
advent
imatinib
im
mesyl
breakpoint
cluster
region
abelson
bcrabl
tyrosin
kinas
inhibitor
tki
time
delay
interest
hht
howev
de
novo
acquir
resist
tki
renew
interest
altern
firstinclass
simpl
natur
ester
cet
hht
current
approv
europ
unit
state
due
report
activ
patient
cml
resist
current
avail
tki
result
septemb
orphan
design
grant
european
union
om
intern
nonproprietari
name
inn
trade
name
synribo
hht
treatment
cml
stragen
franc
sa
franc
treatment
cml
exploit
right
transfer
chemgenex
europ
sa
franc
januari
subsequ
teva
pharma
gmbh
germani
decemb
due
differ
mechan
action
combin
tki
repres
attract
treatment
option
recent
octob
hht
synribo
formerli
ceflatonin
omapro
receiv
acceler
approv
us
food
drug
administr
fda
adult
patient
chronicphas
cp
acceleratedphas
ap
cml
resist
intoler
two
tki
us
fda
grant
full
approv
hht
drug
substanc
inn
om
synribo
inject
base
final
analysi
two
phase
ii
trial
evalu
efficaci
toler
data
omacetaxin
renew
interest
isol
character
biolog
evalu
total
synthesi
cephalotaxu
alkaloid
analog
suppress
depend
natur
sourc
suppli
cephalotaxan
skeleton
either
one
two
unit
coval
link
form
dimer
two
ident
differ
unit
fig
cephalotaxan
includ
neutral
compound
salt
basic
skeleton
common
may
contain
variou
oxygen
substitu
aliphat
ether
aromat
unit
free
esterifi
alcohol
substitut
free
enol
phenol
other
cephalotaxan
includ
cet
character
free
alcohol
function
ring
r
h
ht
group
esterifi
r
h
isol
cephalotaxan
homoerythrinan
alkaloid
skeleton
plant
suggest
might
form
similar
biogenet
rout
hainanensin
structur
uniqu
cephalotaxu
alkaloid
devoid
optic
activ
lack
spiran
tetrasubstitut
carbon
center
isol
cephalotaxu
hainanensi
c
fortunei
fig
display
type
singl
rearrang
cet
skeleton
figur
cephalotaxan
skeleton
minor
homoerythrinan
alkaloid
structur
uniqu
cephalotaxu
alkaloid
hainanensin
compound
relat
cet
seri
tabl
describ
natur
ester
dimer
cet
hht
also
isol
convent
fruit
leav
branch
cephalotaxu
sinensi
among
alkaloid
deriv
cet
compound
possess
differ
ring
cephalotaxinon
demethylcephalotaxin
isocephalotaxinon
ring
c
cephalotaxinamid
oxygen
compound
modif
b
ring
compound
oxygen
bridg
ring
b
drupacin
also
describ
fig
convert
drupacin
acid
medium
among
minor
alkaloid
isol
bark
c
hainanensi
li
addit
known
alkaloid
cet
analog
identifi
cephalotaxinon
cephalotaxinamid
demethylneodrupacin
possess
ether
bridg
drupracin
exhibit
ether
bridg
structur
desmethylcephalotaxinon
isol
cephalotaxu
harringtonia
tabl
cephalotaxu
alkaloid
describ
natur
sourc
till
cephalotaxin
analog
cephalotaxin
c
h
mp
c
c
etoh
hainanensin
c
h
mp
c
ch
oh
epicephalotaxin
c
h
mp
c
c
chci
cephalotaxinon
c
h
mp
c
c
chci
desmethylcephalotaxin
c
h
mp
c
c
ch
oh
demethylcephalotaxinon
c
h
mp
c
c
ch
oh
isocephalotaxinon
c
h
mp
c
c
chci
oxyoen
cephalotaxin
c
h
mp
c
c
chci
c
h
c
c
ch
oh
drupacin
c
h
mp
c
c
c
chci
demethylneodrupacin
c
h
mp
c
cephalotaxinamid
c
h
mp
c
mp
c
c
chci
isoharringtonin
c
h
mp
c
c
chci
deoxyharringtonin
c
ester
oxygen
cephalotaxin
analog
drupangtonin
c
h
oil
c
meoh
c
h
oil
c
meoh
c
h
oil
c
meoh
c
h
oil
c
meoh
forb
k
koch
var
harringtonia
cv
fastigiata
determin
semisynthesi
cet
via
oxid
cephalotaxinon
cleavag
enol
ether
thu
confirm
desmethyl
cet
natur
metabolit
biosynthet
intermedi
repeat
chromatographi
alkaloid
fraction
ethanol
extract
cephalotaxu
fortunei
hook
f
afford
minor
compon
recent
also
identifi
cephalotaxu
koreana
nakai
epicephalotaxin
anoth
minor
metabolit
c
fortunei
hook
f
accompani
cet
total
alkaloid
cephalotaxinon
acetylcet
demethylcet
ht
hht
molecul
coupl
side
chain
bear
ester
function
nordeoxyharringtonin
nordeoxyht
homodeoxyharringtonin
homodeoxyht
deoxyhht
bishomodeoxyharringtonin
bishomodeoxyht
found
among
ht
fig
includ
ester
compound
ester
cet
polycycl
core
coupl
differ
side
chain
deriv
r
citramal
acid
although
occurr
enantiomer
pair
famili
plant
unusu
acetylcephalotaxin
acetylcet
report
enantiomer
form
acetylcet
obtain
semisynthesi
acetyl
natur
cet
isol
c
fortunei
c
wilsoniana
opposit
enantiom
acetylcet
isol
c
fortunei
c
hainanensi
although
error
exclud
literatur
data
find
need
confirm
sinc
natur
cephalotaxu
alkaloid
product
one
portrait
opposit
absolut
configur
ac
alkaloid
core
anhydroharringtonin
bear
addit
heterocycl
side
chain
natur
ester
type
induc
growth
inhibit
leukemia
cell
line
mgml
level
compar
deoxyht
also
molecul
coupl
side
chain
carri
free
acid
group
fig
desomethylht
harrington
acid
desomethylht
cephalozem
acid
c
homoharrington
acid
also
identifi
metabolit
hht
rat
rabbit
desomethylisoht
isoharrington
acid
other
possess
ester
function
aromat
ring
homoneoht
hydroxyneoht
ester
deliv
biolog
activ
compar
first
four
isol
ester
avail
much
lower
quantiti
plant
first
dimer
cephalotaxu
alkaloid
cephalotaxidin
isol
c
harringtonia
var
drupacea
c
drupacea
dimer
hht
homoharringtonamid
ic
mgml
murin
leukem
cell
line
drupangtonin
activ
ic
nm
murin
leukem
cell
line
four
ester
oxygen
cet
analog
ic
mgml
respect
murin
leukem
cell
line
identifi
c
harringtonia
var
drupacea
fig
sinc
last
review
seri
cephalotaxu
alkaloid
isol
variou
cephalotaxu
sp
new
alkaloid
includ
follow
compound
noxid
cet
cet
noxid
cet
b
noxid
b
noxid
togeth
isocephalotaxin
identifi
character
ethyl
acet
extract
c
fortunei
fruit
jossang
et
al
fig
although
describ
synthet
compound
earlier
rel
configur
isocephalotaxin
isol
work
remain
unknown
due
lack
nuclear
overhaus
effect
spectroscopi
noesi
correl
alkaloid
exhibit
low
cytotox
nasopharynx
kb
cell
ic
valu
mgml
respect
ac
cephalezomin
g
h
describ
kobayashi
morita
leav
cephalotaxu
harringtonia
var
harringtonia
determin
circular
dichroism
cd
cephalezomin
g
cephalezomin
h
howev
structur
cephalezomin
h
initi
assign
tran
diol
revis
synb
bdiol
total
synthesi
fig
uncertainti
remain
howev
due
diverg
optic
rotat
synthet
natur
compound
new
stereoisom
desmethylcephalotaxinon
isol
leav
heartwood
formosan
c
wilsoniana
fig
although
uv
nmr
compound
similar
natur
desmethylcephalotaxinon
signal
cephalotaxu
alkaloid
synthet
sampl
evid
compound
stereoisom
desmethylcephalotaxinon
also
base
crosspeak
noesi
correl
chart
correl
seem
doubt
sinc
one
stereogen
carbon
center
present
structur
find
impli
second
stereogen
center
nitrogen
atom
lost
fast
invers
properti
observ
xray
studi
show
rigid
structur
cet
compound
show
cytotox
activ
hep
hep
human
cancer
cell
line
phytochem
investig
branch
leav
cephalotaxu
lanceolata
cephalotaxu
speci
nativ
yunnan
provinc
china
result
isol
three
new
cephalotaxu
alkaloid
cephalancetin
b
unsymmetr
dimer
cephalancetin
togeth
known
cephalancetin
c
isol
first
time
plant
along
nine
known
alkaloid
fig
structur
cephalancetin
c
unambigu
confirm
singlecryst
xray
diffract
consist
cet
link
cephalotaxinamid
thu
establish
ac
cephalancetin
dimer
consist
drupacin
link
cephalotaxinamid
cephalancetin
c
ident
saponif
product
biscephalezomin
see
fig
lioh
isol
alkaloid
test
cytotox
four
human
tumor
cell
line
evidenc
ht
hht
strongli
inhibit
prolifer
human
tumor
cell
line
well
howev
limit
potenc
cell
tabl
ht
show
remark
cytotox
cell
line
ic
valu
mgml
respect
hht
also
exhibit
potent
cytotox
cell
line
ic
valu
mgml
respect
time
stronger
doxorubicin
dox
cell
line
compar
relationship
structur
cytotox
ester
side
chain
cet
skeleton
seem
play
promin
role
cytotox
activ
alkaloid
four
new
cephalotaxu
alkaloid
cephalotin
a
e
isol
leav
twig
c
lanceolata
cephalotaxu
fortunei
var
alpina
yunnan
provinc
pr
china
along
known
alkaloid
fig
none
compound
show
signific
activ
hela
gastric
cancer
lung
cancer
cell
line
ic
mm
kobayashi
et
al
isol
leav
cephalotaxu
harringtonia
var
nana
new
cytotox
alkaloid
cephalezomin
b
ester
drupacin
well
cephalezomin
cef
e
ester
cet
fig
new
compound
found
togeth
seven
known
alkaloid
ester
ht
isoht
deoxyht
homodeoxyht
cet
relat
cet
alkaloid
demethylcet
drupacin
structur
stereochemistri
elucid
spectroscop
data
cd
xray
diffract
analysi
among
new
cephalotaxu
alkaloid
possess
cet
type
backbon
variou
side
chain
cephalezomin
first
one
r
ac
studi
team
kobayashi
also
describ
cytotox
alkaloid
kb
cell
line
tabl
two
year
later
kobayashi
morita
report
isol
five
new
alkaloid
cephalezomin
g
h
jel
leav
c
harringtonia
var
nana
sapporo
japan
among
cephalezomin
k
l
ester
cet
epim
fig
biscephalezomin
homodeoxyht
two
hht
noxid
hht
noxid
hht
b
noxid
previous
prepar
takano
sar
studi
fig
hht
ht
show
pronounc
antiplasmodi
activ
plasmodium
falciparum
lesser
extent
leishmania
major
tabl
deoxyht
homodeoxyht
activ
two
test
figur
oxygen
cephalotaxu
ester
cephalozemin
j
hht
noxid
hht
b
noxid
report
first
time
natur
product
display
antileishmani
cytotox
activ
cell
line
despit
esterifi
function
structur
tabl
sar
direct
toward
antiplasmodi
activ
isol
cephalotaxu
alkaloid
also
discuss
cephalezomin
j
leav
c
harringtonia
var
nana
fig
uniqu
cet
conjug
sugar
type
side
chain
dglucos
although
data
collect
studi
cytotox
valu
tabl
select
index
calcul
rate
effect
human
versu
parasit
cell
line
case
cytotox
greater
parasit
rather
tumor
cell
si
kobayashi
et
al
isol
five
new
dimer
alkaloid
c
harringtonia
var
nana
especi
heterodim
name
biscephalezomin
aee
e
fig
alkaloid
constitut
dimer
hht
ht
deoxyht
cephalezomin
show
potent
cytotox
new
alkaloid
cephalocyclidin
unpreced
polycycl
rearrang
skeleton
deriv
cet
six
contigu
asymmetr
center
isol
fruit
c
harringtonia
var
nana
ac
assign
exciton
chiral
method
respect
indic
configur
compat
absolut
stereochemistri
hydrochlorid
cet
deduc
flack
paramet
xray
analysi
could
deriv
biogenet
format
cephalocyclidin
mous
lymphoma
human
epidermoid
carcinoma
cell
kb
mgml
respect
proport
four
major
natur
ester
antitumor
activ
needl
c
fortunei
root
c
harringtonia
var
harringtonia
total
amount
alkaloid
plant
best
natur
sourc
four
compound
pharmacolog
interest
present
plant
genu
cephalotaxu
endang
speci
face
threat
extinct
renew
part
plant
use
extract
alkaloid
exampl
use
modern
method
extract
provid
kg
pure
cet
ton
dri
leav
dri
matter
robin
et
al
studi
method
prepar
hht
semisynthesi
natur
cet
attach
side
chain
see
section
purif
provid
product
puriti
nci
product
product
chines
origin
tabl
exampl
g
hht
inject
prepar
highperform
liquid
chromatographi
hplc
system
diamet
cm
height
contain
kg
od
stationari
phase
elut
perform
use
gradient
buffer
solut
ph
methanolwat
mobil
phase
flow
rate
lh
psi
collect
fraction
l
separ
uv
detect
analyz
hplc
elimin
fraction
total
content
hht
fraction
suitabl
drug
specif
puriti
combin
hplc
analysi
organ
phase
hht
recoveri
basifi
ph
extract
dichloromethan
show
level
impur
less
hht
g
recrystal
dissolut
ml
methanol
c
filter
micron
steril
deioniz
water
l
ad
methanol
distil
aqueou
solut
hht
ds
qualiti
drug
substanc
drug
substanc
qualiti
ds
held
decontamin
rotari
evapor
appear
white
crystal
pure
hht
filtrat
dri
vacuum
c
day
overal
yield
oy
hht
obtain
compar
potenti
content
semisynthet
gross
hht
correspond
clinic
batch
allow
prepar
therapeut
dosag
unit
contain
mg
contain
less
impur
numer
method
describ
extract
purif
cet
natur
ester
relat
analog
extract
fruit
leav
branch
c
sinensi
ethanol
reflux
condit
follow
acid
base
treatment
purif
alumina
allow
isol
cet
hht
high
speed
countercurr
chromatographi
form
liquideliquid
partit
chromatographi
stationari
liquid
phase
retain
apparatu
without
use
solid
support
perform
ph
gradient
elut
shorten
durat
separ
improv
resolut
allow
effici
separ
crude
alkaloid
extract
mg
c
fortunei
yield
drupacin
mg
wilsonin
mg
cet
mg
epiwilsonin
mg
fortunein
mg
acetylcet
recoveri
alkaloid
greater
extract
step
play
import
role
overal
purif
process
hht
tradit
method
isol
purif
chemic
constitu
plant
tissu
disadvantag
approach
requir
long
extract
time
usual
larg
amount
solvent
sometim
low
effici
furthermor
mani
natur
product
thermal
unstabl
may
degrad
hot
extract
overcom
drawback
new
method
extract
hht
cephalotaxu
koreana
use
microwav
extract
mwe
develop
kim
et
al
mwe
process
hht
recoveri
biomassmeoh
mv
rpm
gave
perform
first
biomass
extract
higher
convent
solvent
extract
cse
method
least
four
extract
requir
possibl
recov
hht
extract
biomass
mwe
c
min
c
min
content
tar
waxi
compound
also
increas
adsorb
ad
biomass
mm
mwe
extract
use
mwe
process
extract
hht
compar
cse
one
mani
advantag
shorter
extract
time
reduc
amount
solvent
higher
yield
result
less
costli
product
system
superior
product
ultrasonicmw
c
fortunei
produc
cet
simpl
highli
effici
low
cost
process
suitabl
industri
product
high
puriti
two
recrystal
anhydr
ethanol
use
prepurif
method
adsorpt
prior
chromatographi
hht
puriti
obtain
simpli
c
koreana
biomass
good
yield
minim
use
solvent
scale
complex
oper
final
hplc
purif
hht
tabl
process
allow
increas
puriti
raw
hht
three
simpl
step
inexpens
pretreat
meoh
extract
recent
studi
robin
relat
method
isol
purif
cet
crude
alkaloid
extract
kg
dri
leav
bark
c
fortunei
var
alpina
sichuan
china
cet
purif
perform
first
time
revers
phase
hplc
crude
base
g
contain
cet
dissolv
mobil
phase
consist
orthophosphor
acid
deioniz
water
contain
triethylamin
ph
acid
addit
constrain
alkal
obtain
aqueou
phase
extract
dichloromethan
cet
g
fulli
recov
crude
alkaloid
extract
white
solid
hplc
puriti
greater
limit
suppli
promis
secondari
metabolit
natur
sourc
major
hurdl
pharmaceut
develop
howev
strategi
overcom
problem
develop
instanc
increas
yield
natur
anticanc
drug
alkaloid
natur
sourc
method
extract
develop
recov
cet
c
harringtonia
var
fastigiata
veget
oil
presenc
aqueou
carbon
aqueou
phase
yield
cet
puriti
extract
perform
mixtur
scco
supercrit
co
et
nh
yield
cet
undescrib
puriti
hht
also
obtain
c
koreana
et
al
develop
hplc
analysi
method
hht
determin
allow
reveal
three
congen
present
impur
hht
sampl
two
impur
new
aisohht
isom
hht
hydroxyl
group
alpha
isopropyl
group
ethylhht
ethyl
ester
hht
isol
artifact
hht
ethyl
acet
third
ht
tabl
prepurif
summari
step
homoharringtonin
hht
biomass
g
step
hht
tabl
aisohht
found
concentr
crystal
mother
liquor
hht
crude
extract
hplc
analysi
accord
protocol
therefor
allow
determin
hht
crude
sampl
linear
respons
mg
limit
quantit
loq
mg
use
assess
puriti
sever
hht
commerci
batch
tandem
hplcelectronspray
mass
spectrometri
msem
method
develop
analysi
alkaloid
contain
leav
c
harringtonia
nine
alkaloid
bear
ester
group
detect
good
sensit
content
ht
higher
hht
needl
cephalotaxu
griffithii
alkaloid
fraction
cgaf
mgg
cgaf
respect
hplc
analysi
anoth
major
concern
enantiomer
puriti
cet
direct
effect
diastereoisomer
puriti
natur
ester
process
purif
hht
earli
develop
view
clinic
studi
although
recent
new
process
purif
cet
allow
resolut
racem
partial
racem
sampl
studi
also
point
cristallin
structur
hht
deposit
cambridg
crystallograph
data
centr
ccdc
exhibit
revers
ac
commonli
accept
one
eventu
select
cephalotaxu
cultivar
grown
europ
allow
high
recov
cet
g
highli
pure
cristallin
cet
kg
dri
leav
similarli
ammonium
salt
ht
hht
character
expect
proton
occur
find
accord
biolog
studi
noxid
takano
mechanist
studi
steitz
see
section
apart
extract
natur
sourc
plant
cell
cultur
repres
altern
effici
sustain
chemic
factori
product
biolog
import
secondari
metabolit
especi
natur
sourc
becom
endang
product
limit
low
yield
associ
harvest
high
cost
associ
complex
chemic
synthesi
cephalotaxu
evergreen
tree
somewhat
difficult
propag
rel
rare
list
red
list
iucn
intern
union
conserv
natur
nation
plant
secondgrad
protect
china
near
threaten
cephalotaxu
latifolia
vulner
cephalotaxu
oliveri
cephalotaxu
mannii
rare
endang
c
lanceolata
cephalotaxu
fortunei
hook
var
lanceolata
kmfeng
silba
c
hainanensi
speci
varieti
strategi
develop
overcom
limit
low
product
yield
renew
interest
studi
cephalotaxu
crop
develop
method
analyz
composit
differ
plant
stimul
need
raw
materi
search
natur
sourc
rich
cet
hplc
protocol
use
determin
content
cet
ht
hht
crop
root
callus
c
harringtonia
expect
cet
major
alkaloid
mgkg
dri
matter
ht
hht
present
root
mgkg
respect
plant
cell
tissu
cultur
cell
growth
product
format
necessarili
correl
cell
cultur
studi
sought
identifi
factor
tend
yield
low
yield
slow
metabol
rate
zhang
et
al
propos
techniqu
period
oscil
temperatur
c
everi
h
day
overcom
key
problem
total
product
ht
hht
isoht
mgl
solid
cultur
soc
c
fortunei
enhanc
compar
control
constant
temperatur
c
subject
oscil
everi
h
day
suspens
cultur
suc
gave
total
alkaloid
product
mgl
improv
compar
suc
control
c
respect
ht
repres
main
alkaloid
soc
day
suc
day
hht
content
soc
suc
remain
isoht
li
show
combin
mgl
sodium
fluorid
naf
glycometabol
regul
mmoll
methyl
jasmon
mj
elicitor
promot
biosynthesi
cet
c
mannii
suspens
cell
naf
effect
increas
cell
membran
permeabl
product
secret
compar
mj
yield
ht
cell
greater
naf
mj
condit
control
greater
naf
mj
condit
respect
tabl
hht
found
naf
mjetreat
cell
product
releas
rate
control
naf
mj
naf
mj
treatment
respect
combin
naf
mj
treatment
cell
provid
effici
strategi
produc
cet
anoth
studi
effect
action
mechan
naf
growth
cet
product
c
mannii
suspens
cell
indic
naf
act
inhibitor
embdenemeyerhof
pathway
emp
elicitor
promot
cet
product
cephalotaxu
alkaloid
drawn
attent
mani
chemist
due
uniqu
structur
potent
antileukem
activ
certain
ester
deriv
contain
excel
review
articl
subject
publish
seri
huang
xue
miah
et
al
recent
among
other
nay
et
al
sinc
synthes
cet
report
enantioselect
cet
describ
superposit
two
structur
unit
relev
synthet
strategi
name
pyrrolobenzazepin
core
abc
synthet
challeng
azaspiro
unit
cd
scheme
three
stereogen
center
contigu
ring
weinreb
show
stereochemistri
bd
ring
fusion
thermodynam
favor
addit
carbonyl
reduct
cephalotaxinon
deliv
cet
natur
configur
sinc
describ
review
synthes
cet
concern
racem
form
tabl
number
asymmetr
synthes
grown
consider
inflect
develop
asymmetr
synthesi
effort
provid
fulli
synthet
access
drug
tabl
present
section
describ
recent
synthet
strategi
organ
accord
main
carbonecarbon
bond
disconnect
central
azepin
ring
b
fig
asymmetr
synthes
also
classifi
base
type
asymmetr
center
control
key
step
highlight
strategi
synthes
formal
nevertheless
oy
synthesi
cet
evalu
eight
racem
five
asymmetr
synthes
cet
total
synthes
one
racem
three
asymmetr
rout
describ
sinc
experiment
oy
enantiomer
excess
ee
oy
cephalotaxu
alkaloid
number
step
ns
given
commerci
avail
reagent
comparison
purpos
addit
converg
synthes
total
number
step
tn
repres
total
effort
accomplish
target
molecul
correspond
averag
yield
ay
given
synops
synthes
cet
report
far
present
tabl
racem
tabl
asymmetr
besid
formal
synthes
target
weinreb
enamin
group
togeth
tabl
racem
synthes
classifi
accord
type
disconnect
ring
b
aee
fig
type
intermedi
formal
synthes
chronolog
order
asymmetr
synthes
present
chronolog
order
tabl
appar
tabl
synthes
raccet
ae
linear
converg
proceed
predominantli
disconnect
shortest
access
cet
describ
first
synthesi
cet
weinreb
et
al
step
includ
prepar
homopiperonyl
acid
two
step
piperon
effect
total
synthes
describ
kuehn
et
al
step
oy
averag
yield
per
step
step
oy
ishibashi
ikeda
et
al
favorit
choic
ring
precursor
piperon
homopiperonyl
acid
methylenedioxi
group
alreadi
right
posit
tabl
show
prolin
wide
use
chiral
sourc
synthes
either
natur
l
form
unnatur
one
herein
synthes
converg
linear
effici
total
synthes
cet
oy
report
weinreb
et
al
oy
ay
step
ee
ikeda
et
al
oy
ay
step
ee
duma
dangelo
oy
step
ee
ay
tn
el
biali
et
al
oy
step
ee
ay
tn
trost
et
al
oy
step
ee
ay
tn
also
effici
ring
closur
fig
form
azepin
cycl
frequent
adopt
semmelhack
earli
extens
develop
second
synthesi
raccet
ae
tietz
formal
synthesi
tietz
et
al
cephalotaxu
alkaloid
oy
ay
tn
mention
mori
protocol
differ
synthesi
racem
optic
activ
cet
inde
transform
desmethyl
cet
cephalotaxinon
use
ptsoh
led
racem
product
yield
contrari
ptsoh
methyl
orthoform
use
transform
room
temperatur
rt
limit
racem
occur
ee
yield
went
suga
yoshida
develop
approach
azaspirocompound
via
ringclos
metathesi
rcm
function
pyrrolidin
gener
electrochem
oxid
abi
trimethylsilyl
pyrrolidin
scheme
first
homopiperonyl
acid
use
prepar
unit
bear
nosyl
aromat
iodid
suitabl
ring
b
annul
reli
semmelhack
procedur
two
silyl
group
introduc
beak
methodolog
deproton
secbuli
quench
tmscl
furnish
compound
protect
nmethoxycarbonyl
compound
anod
oxid
low
temperatur
yield
nacyliminium
ion
react
situ
homoallylmagnesium
bromid
furnish
pyrolidin
latter
compound
next
submit
second
anod
oxid
follow
direct
trap
organozinc
reagent
provid
diolefin
dien
convert
azaspiro
cd
unit
via
ring
close
metathesi
promot
grubb
catalyst
deprotect
use
tmsi
spiran
amin
intermedi
react
nosyl
obtain
homopiperonyl
acid
follow
semmelhack
procedur
soform
aryl
iodid
ae
submit
intramolecular
hecktyp
ring
close
reaction
accord
tietz
regioselect
bromin
homopiperonyl
acid
yield
bromocarboxyl
acid
convert
weinreb
amid
reduc
dibal
furnish
aldehyd
differ
rout
propos
prepar
acd
ringecontain
aryl
bromid
best
one
start
bketoest
transform
reduct
allyl
alcohol
treat
triethyl
orthoacet
johnson
orthoester
claisen
condit
give
ethyl
ester
afterward
ester
convert
three
step
sulfonamid
success
reduct
lialh
tosyl
nucleophil
displac
tosylamin
gbutyrolactam
prepar
oy
mitsunobu
substitut
primari
alcohol
follow
partial
reduct
crude
succinimid
nabh
reduct
dehydroxyl
result
hemiamin
huang
methodolog
name
activ
compound
triflic
anhydrid
dtbmp
best
base
reaction
follow
success
addit
grignard
employ
suga
yoshida
four
step
mori
protocol
perform
obtain
raccet
ae
give
pathway
estim
oy
homopiperonyl
acid
reaction
situ
gener
dimethylsulfonium
methylid
gave
allyl
alcohol
directli
use
subsequ
johnsoneclaisen
rearrang
result
ester
subject
amid
reaction
condit
hydroxylamin
afford
hydroxam
acid
nitrosoen
cycliz
accomplish
oxid
tetrapropylammonium
period
via
highli
reactiv
acylnitroso
intermedi
deliv
trap
acet
yield
moder
yield
spirolactam
ae
smi
reduct
alkyl
sodium
salt
ae
iodoaryl
tosyl
gave
quantit
ae
subsequ
heck
reaction
promot
herrmannebel
catalyst
proceed
smoothli
deliv
abcd
kuehn
intermedi
ae
correspond
regioisomer
product
ae
combin
yield
base
recov
start
materi
brsm
insepar
mixtur
raccet
ae
could
obtain
step
cyclopenten
oxid
oy
provid
separ
regioisom
effect
four
supplementari
step
appli
transform
abcd
intermedi
ae
tn
step
ay
brsm
although
huang
wang
describ
rapid
access
cd
spirocycl
amid
ae
heck
ring
closur
ring
b
led
mixtur
two
regioisom
decreas
dramat
yield
key
transform
describ
best
rout
led
li
intermedi
ae
via
spirolacton
scheme
spirolacton
obtain
methyl
prolin
ae
nallyl
allyl
bromid
lead
allylamin
underw
steven
rearrang
result
quaternari
ammonium
salt
reaction
benzyl
bromid
provid
nbenzyl
pyrrolidin
lacton
acid
condit
follow
debenzyl
catalyt
hydrogen
spirolacton
acyl
chlorid
produc
amid
spirolacton
contain
ac
ring
unit
select
reduc
libh
diol
oy
swern
oxid
diol
furnish
amido
ketoaldehyd
treat
potassium
carbon
give
amido
spirocyclopentenon
ae
acd
ring
unit
formal
synthesi
especi
suitabl
product
ae
scale
g
li
hanaoka
procedur
step
oy
would
allow
complet
synthesi
raccet
ae
step
oy
racprolin
ae
zhang
et
al
propos
two
pathway
formal
synthesi
raccet
ae
target
li
enon
ae
hanaoka
enon
ae
base
convent
alkyl
aldol
condens
known
benzazepin
obtain
four
step
aryl
amin
bear
methylenedioxi
substitu
bear
two
methoxi
substitu
respect
scheme
c
ring
elabor
via
nand
calkyl
annul
treatment
benzazepin
cs
co
give
product
one
step
abc
dion
prepar
alkyl
either
allyl
bromid
follow
wacker
oxid
effici
bromid
follow
acid
hydrolysi
scheme
aldol
condens
effici
construct
cet
core
ae
dimethoxi
group
transform
requir
methylenedioxi
group
usual
protocol
altern
synthesi
author
also
studi
use
methylenedioxybenzazepin
start
materi
scheme
ring
c
elabor
acylationalkyl
benzazepin
chlorid
furnish
abc
keton
treatment
sodium
hydrid
bromid
produc
enol
ether
major
oalkyl
product
along
desir
calkyl
deriv
claisen
rearrang
allow
convers
expos
acid
hydrolysi
give
dion
intramolecular
aldol
condens
provid
known
amido
enon
ae
follow
hanaoka
synthesi
total
step
homopiperonyl
acid
estim
oy
bubnov
et
al
develop
conveni
practic
methodolog
prepar
variou
spirobamino
alcohol
procedur
appli
formal
synthesi
raccet
ae
involv
allylbor
rcm
prepar
cd
ring
contain
azaspirobicycl
compound
scheme
start
piperonyl
amin
diester
obtain
four
step
via
bishlerenapieralski
cycliz
follow
hydrogen
nalkyl
ethyl
second
nalkyl
allyl
bromid
led
ammonium
salt
intermedi
transform
via
steven
rearrang
diester
eventu
compound
obtain
dieckmann
cycliz
subsequ
decarboxyl
follow
wacker
oxid
aldol
condens
dion
provid
spirocycl
ad
enon
scheme
cet
b
c
ring
form
reduct
rearrang
acet
acid
via
aziridinium
ion
obtain
abcd
keton
ae
revis
stereochemistri
drawn
oxid
phenyliodonium
diacet
give
acet
ae
hydrolysi
submit
autoxid
dehydrogen
potassium
tbutoxid
oxygen
provid
desmethylcephalotaxinon
ae
formal
synthesi
raccet
ae
could
achiev
accord
weinreb
use
two
addit
step
lead
formal
total
synthesi
calcul
oy
step
piperon
altern
approach
keton
ae
describ
allyl
keton
clemmensen
reduct
rearrang
keton
first
led
benzazepin
deriv
scheme
wacker
oxid
compound
applic
polonovski
potier
reaction
condit
gave
enamin
previous
report
cycliz
intermedi
ae
formal
endocycl
enamin
annul
could
realiz
low
yield
li
found
aerob
treatment
fe
salt
acet
acid
promot
cycliz
abcd
enon
ae
good
yield
cycliz
seen
unusu
azonazarovtyp
cycliz
catalyt
hydrogen
eventu
gave
keton
ae
synthesi
six
step
oy
advantag
compar
three
step
oy
version
present
scheme
thu
formal
synthesi
raccet
ae
follow
procedur
could
theoret
achiev
step
oy
piperon
li
et
al
describ
formal
synthesi
dolbyeweinreb
enamin
dion
mild
clemmenseneclemo
reduct
rearrang
key
step
scheme
dehydrogen
benzazepin
hg
oac
gave
enamin
could
like
transform
raccet
ae
weinreb
strategi
expect
oy
step
piperon
reduct
rearrang
aminodion
also
produc
aminoketon
yield
could
process
demethylcephalotaxinon
cet
ninestag
sequenc
constitut
anoth
formal
synthesi
cet
expect
oy
step
piperon
li
report
novel
synthesi
amino
enon
involv
annul
readili
avail
aminodion
scheme
bischlerenapierralski
condens
amin
dvalerolacton
mediat
pocl
gave
iminium
ion
yield
treatment
aqueou
naoh
gener
labil
enamin
alkyl
bromoaceton
give
keto
enamin
iminium
bromid
transform
treatment
perchlor
acid
iminium
perchlor
exposur
naoh
furnish
unexpect
dion
annul
ciscyclopentanon
base
intramolecular
schmidt
reaction
symmetr
azido
dion
scheme
synthesi
start
compound
ring
precursor
obtain
homopiperonyl
acid
reduct
bromat
chlorin
iodocyclopentenon
ring
precursor
prepar
iodin
cyclopentenon
scheme
cephalotaxu
alkaloid
z
isom
mild
hydrid
reduct
led
hydroxi
enon
presum
via
oxonium
ion
could
underw
rapid
effect
electrocycl
acetyl
hydroxyl
function
result
compound
follow
select
cleavag
ntroc
group
zinc
reduct
led
spontan
format
abcd
unit
singl
diastereom
intramolecular
azamichael
addit
airoxid
presenc
potassium
tbutoxid
gave
racdemethylcephalotaxinon
ae
applic
weinreb
method
would
allow
synthes
raccet
ae
step
piperon
oy
submit
mild
sonogashira
condit
afford
alkyn
intermolecular
pausonekhand
reaction
alkyn
ethylen
could
gener
two
regioisomer
product
desir
isom
yield
obtain
optim
condit
use
nbutyl
methyl
sulfid
promot
dimethyl
sulfoxid
oxid
oxid
alcohol
follow
reduct
amin
produc
amin
advanc
ring
compound
intramolecular
nalkyl
mariano
intermedi
prepar
success
deprotect
reprotect
tbutoxycarbonyl
group
strategi
led
quickli
effici
macrocycl
precursor
eight
step
oy
compound
hand
formal
synthesi
raccet
ae
thu
attain
addit
fivestep
sequenc
would
give
raccet
ae
step
homopiperonyl
acid
estim
oy
recent
hong
et
al
report
two
formal
synthes
involv
unusu
disconnect
b
ring
b
format
fig
key
step
first
nacyliminium
ion
cycliz
establish
stereogen
center
format
b
ring
rcm
furnish
spiror
two
synthes
start
iodo
alcohol
prepar
homopiperonyl
acid
two
step
sonogashira
coupl
aryl
iodid
propargyl
trimethylsilan
catalyz
palladium
ii
copper
iodid
deliv
alkyn
excel
yield
scheme
catalyst
screen
partial
hydrogen
carri
nickel
ethylenediamin
brown
catalyst
lead
z
quantit
yield
dr
mitsunobu
reaction
succinimid
follow
allyl
next
gave
hemiamin
treat
ticl
low
temperatur
mesitylen
allow
gener
nacyliminium
ion
cycliz
furnish
abc
unit
cistran
zhan
effect
rcm
reaction
deliv
kuehn
intermedi
ae
formal
synthesi
raccet
ae
could
achiev
kuehn
protocol
step
homopiperonyl
acid
calcul
oy
sinc
iminium
ion
cycliz
show
moder
diastereoselect
separ
two
diastereom
silica
gel
chromatographi
fail
rout
less
attract
improv
author
investig
cycliz
eallylsilan
obtain
suzuki
coupl
compound
aryl
iodid
catalyz
palladium
scheme
previous
seen
mitsunobu
reaction
gave
subsequ
treat
grignard
reagent
cycliz
hosomiesakurai
reaction
ticl
promot
iminium
ion
cycliz
abc
pyrrolobenzazepin
obtain
ratio
favor
transisom
rcm
reaction
transisom
amid
happen
whatev
catalyst
use
reduct
amid
led
less
rigid
tertiari
amin
suitabl
desir
cycliz
metathesi
proceed
smoothli
presenc
camphor
sulfon
acid
equiv
proton
amin
catalyst
mol
abcd
ring
system
obtain
invert
rel
stereochemistri
dihydroxyl
swern
oxid
afford
known
demethylcephalotaxinon
ae
applic
improv
weinreb
procedur
would
gener
raccet
ae
step
expect
oy
homopiperonyl
acid
end
synthesi
raccet
ae
scheme
unusu
bond
format
amid
reaction
close
b
ring
fig
aldehyd
deriv
five
step
lprolin
synthesi
optic
pure
cet
remain
challeng
organ
chemist
three
contigu
asymmetr
center
includ
tetrasubstitut
one
ring
control
earli
notic
weinreb
racem
synthes
led
one
diastereoisom
without
requir
separ
mean
configur
three
asymmetr
center
mutual
control
strategi
use
disconnect
b
ring
format
exemplifi
phenomenon
cycliz
step
thermodynam
stabl
bd
ring
junction
ci
rel
configur
found
natur
cet
moreov
weinreb
also
show
nabh
reduct
cephalotaxinon
stereoselect
scheme
deliv
requir
rel
stereochemistri
hydroxyl
function
cet
assum
form
result
hydrid
attack
convex
face
thu
possibl
control
success
center
via
tetrasubstitut
center
center
via
stereocent
cephalotaxu
alkaloid
consequ
control
tetrasubstitut
stereocent
necessari
one
synthet
enantiomer
pure
cet
asymmetr
synthes
base
control
spiro
center
follow
stereoselect
cycliz
afford
b
ring
control
final
reduct
establish
desir
configur
asymmetr
synthes
cet
describ
classifi
accord
type
stereochem
control
asymmetr
catalysi
use
chiral
auxiliari
incorpor
chiral
build
block
resolut
strategi
deconnect
ring
b
relat
strategi
chronolog
order
section
treatment
larg
excess
grignard
reagent
prepar
chloroalcohol
tosyl
three
step
oy
chiral
bromoacet
correspond
futur
ring
obtain
reduct
diboran
presenc
catalyt
amount
chiral
oxazaborolidin
follow
acetyl
allyl
alcohol
ee
measur
nmr
use
eu
hfc
format
b
c
ring
achiev
strategi
describ
raccet
ae
employ
two
success
pdcatalyz
transform
optic
activ
form
mori
intermedi
isol
synthesi
cet
could
like
achiev
linear
sequenc
calcul
oy
expect
ee
applic
tietz
procedur
led
mori
alken
ee
determin
chiral
hplc
surprisingli
purif
column
chromatographi
silica
gel
author
found
enantiom
could
separ
lead
yield
ee
phenomenon
call
selfdisproporn
enantiom
result
differ
affin
aggreg
compound
silica
gel
tu
thu
accomplish
formal
synthesi
cet
step
calcul
oy
ee
tn
oy
high
puriti
materi
estim
ee
could
obtain
calcul
oy
trimethylsilylacetylen
renaud
et
al
report
two
variant
formal
synthesi
cet
synthes
base
stereoselect
carboazid
methylen
cyclopentanol
deriv
first
approach
describ
later
see
section
scheme
start
materi
obtain
racem
resolut
second
approach
effici
start
cyclopentenol
obtain
ee
set
via
enantioselect
noyori
hydrogen
propargyl
keton
use
give
compound
obtain
yield
acid
scheme
dihydroxyl
silyl
enol
afford
diol
singl
diastereoisom
protect
acetonid
desilyl
oxid
wittig
methylen
afford
bicycl
alken
submit
radic
carboazid
reduct
azid
first
stereogen
center
cet
number
cyclopentenol
use
control
configur
newli
form
diol
destroy
doubl
bond
format
chiral
center
eventu
control
carboazid
step
lead
sequenc
correspond
concept
selfregener
stereogen
center
phosphoramidit
ligand
provid
chiral
cycloaddit
deliv
compound
ee
chiral
hplc
transform
compound
ae
raccet
previous
report
ikeda
formal
entcet
enantiom
natur
product
could
obtain
expect
ee
calcul
oy
step
ll
piperon
royer
et
al
describ
asymmetr
synthesi
azaspiro
compound
contain
cd
ring
fragment
exploit
stereoselect
semipinacol
reaction
key
step
author
develop
enantioselect
synthesi
cet
spirolactam
ketal
reli
kuehn
furnish
desir
spiro
compound
nacyliminium
ion
attack
prefer
anti
naphtyl
group
deliv
compound
good
diastereoisomer
excess
de
major
diastereoisom
recrystal
also
easili
recov
chromatographi
thu
azaspirononanedion
obtain
yield
de
surpass
keton
function
protect
cyclic
ketal
reduct
cleavag
nbenzyl
bond
provid
spirolactam
ketal
nalkyl
sodium
salt
tosyl
follow
ketal
hydrolysi
afford
enantiopur
acd
intermedi
describ
kuehn
racem
form
follow
kuehn
procedur
compound
transform
cet
improv
format
enon
use
stoichiometr
amount
pd
oac
without
benzoquinon
yield
modif
consist
use
alh
c
instead
lialh
reflux
tetrahydrofuran
thf
reduct
avoid
racem
sensit
cet
cet
thu
obtain
ee
oy
linear
sequenc
use
ethylamin
chiral
sourc
explor
abc
abcd
synthet
strategi
duma
dangelo
et
al
report
novel
enantioselect
synthesi
azaspiro
unit
contain
cd
ring
describ
royer
base
asymmetr
michael
reaction
involv
chiral
enamin
prepar
cheap
recycl
enantiopur
r
scheme
consequ
stereogen
control
quaternari
carbon
center
result
r
ketodiest
two
asymmetr
center
cet
form
natur
ac
similarli
use
antipod
could
afford
entcet
although
would
lead
biogol
inact
ester
key
step
curtiu
rearrang
acyl
azid
allow
instal
perfect
stereochem
fidel
high
effici
anitrogen
substitu
tetrasubstitut
center
ketodiest
set
tetrasubstitut
spirocycl
center
ketodiest
r
elabor
yield
ee
michael
addit
enamino
ester
r
methyl
acryl
sequenti
highli
stereoselect
luch
reduct
keton
low
temperatur
follow
saponif
acidif
provid
intermediari
hydroxi
diacid
spontan
lacton
gener
diastereomer
pure
lacton
acid
obtain
yield
two
ester
function
differenti
stage
acid
first
convert
acyl
azid
directli
rearrang
benzyl
carbam
treatment
benzyl
alcohol
c
saponif
follow
oxid
situgener
ruthenium
tetroxid
esterif
intermedi
acid
diazomethan
afford
ketoest
r
compound
convert
ketal
submit
hydrogenolysi
deliv
target
spiroket
amid
reli
royer
kuehn
procedur
ikeda
et
al
develop
asymmetr
version
racem
synthesi
intermedi
abcd
keton
prepar
unnatur
dprolin
r
use
furnish
c
ring
atom
control
tetrasubstitut
stereogen
center
set
scheme
compound
obtain
dprolin
r
accord
seebach
stereoselect
allyl
give
oxalolidinon
react
gener
prepar
benzodioxol
nbuli
c
hay
et
al
develop
formal
synthesi
cet
base
alkyliden
carben
insert
reaction
key
step
construct
nonan
cd
ring
system
first
approach
vinyl
chlorid
chosen
carben
precursor
prepar
seven
step
oy
lprolin
via
nbocprolin
methyl
ester
scheme
dibalh
reduct
follow
wittig
reaction
gave
intermedi
eenon
catalyt
hydrogen
second
wittig
reaction
chloromethylenephosphoran
afford
vinyl
chlorid
deprotect
amin
amid
format
carboxyl
acid
reduct
result
amid
led
pivot
alkyliden
carben
precursor
treatment
potassium
hexamethyldisilazid
caus
key
alkyliden
carben
insert
reaction
lead
desir
azaspiro
nonan
deriv
good
yield
regioselect
iodin
aromat
ring
system
gave
heckcycl
precursor
xray
crystal
structur
allow
confirm
absolut
stereochemistri
thu
demonstr
expect
insert
reaction
proceed
retent
configur
heck
cycliz
modifi
fu
condit
pd
oac
hbf
ptbu
cs
co
deliv
abcd
olefin
yield
togeth
enamin
last
stage
involv
remov
extra
carbon
atom
ring
decarbonyl
aldehyd
toward
end
alken
epoxid
use
dimethyldioxiran
presenc
bf
et
result
epoxid
submit
regioselect
yamamoto
rearrang
lead
allyl
alcohol
protect
acet
transpos
treatment
aqueou
hcl
primari
alcohol
oxid
swern
aldehyd
presenc
wilkinson
catalyst
afford
key
mori
intermedi
cet
could
like
obtain
use
mori
protocol
way
expect
ee
step
calcul
oy
lprolin
second
formal
synthesi
cet
alkyliden
carben
insert
reaction
also
use
establish
key
tetrasubstitut
stereocent
previous
describ
scheme
howev
addit
carbon
atom
phosphoran
previou
tediou
sequenc
remov
atom
ring
longer
requir
seven
step
oy
scheme
carben
precursor
deriv
nboc
prolin
obtain
lprolin
three
step
yield
result
spirocycl
product
carben
insert
convert
friedelecraft
cycliz
mori
intermedi
r
r
ch
transform
cet
follow
mori
procedur
scheme
keton
prepar
wittig
reaction
aldehyd
phosporan
protect
hydroxymethyl
moieti
tb
suitabl
carben
insert
thu
treatment
lithium
trimethylsilyldiazomethan
gave
azaspirocycl
convert
nboc
spiroamin
success
deprotect
oxid
decarbonyl
good
yield
racem
occur
tetrasubstitut
stereocent
ndeprotect
compound
first
subject
epoxid
epoxid
isol
immedi
treat
lewi
acid
provid
major
product
alcohol
transform
cd
amino
alcohol
via
tosyl
elimin
dbu
deliv
intermedi
cyclopenten
three
essenti
step
use
djaballah
gin
et
al
synthesi
cet
scheme
first
nitrogen
atom
introduc
oxim
follow
neber
rearrang
secondli
construct
benzazepin
core
reli
strainreleas
rearrang
aziridin
eventu
assembl
spirofus
pyrrolidin
core
occur
via
cycloaddit
azomethin
ylide
deriv
vinylog
amid
chiral
introduc
optic
pure
cyclopentenon
substitut
cet
number
prefigur
ring
compound
prepar
dribofuranos
isopropyliden
group
allow
stereocontrol
one
diastereom
obtain
synthesi
began
doubl
protect
dribofuranos
olefin
follow
parikhedo
oxid
furnish
keton
alkyl
vinylmagnesium
bromid
provid
allyl
alcohol
dr
scheme
cyclopenten
prepar
rcm
grubb
ii
regioselect
chloroselenyl
alken
follow
selenid
oxid
elimin
afford
chlorocyclopenten
deprotect
gave
vicin
diol
eventu
chiral
bchloroenon
step
oy
dribofuranos
obtain
periodatemedi
oxid
cleavag
diol
synthesi
featur
ring
cet
scheme
aziridin
prepar
step
scheme
condens
keton
hydroxylamin
chlorhydr
furnish
oxim
react
lialh
diisopropylamin
c
afford
racem
aziridin
nebertyp
reduct
rearrang
additioneelimin
sequenc
start
addit
aziridin
onto
bchloroenon
furnish
nvinyl
aziridin
diastereomer
mixtur
scheme
prepar
heat
aziridin
cs
co
gener
effici
rearrang
via
open
aziridin
compound
nalkyl
tmsch
give
tertiari
vinylog
amid
oactiv
vinylog
amid
group
carri
pivaloyl
triflat
gener
situ
combin
pivaloyl
chlorid
agotf
follow
desilyl
tbat
give
azomethin
ylide
dipolar
cycloaddit
phenyl
vinyl
sulfon
regioselect
afford
spirofus
pyrrolidin
unexpect
way
one
diastereoisom
obtain
isopropylideneket
effect
stereodirect
element
desir
r
configur
determin
singl
crystal
xray
diffract
analysi
radic
desulfur
follow
hydrolysi
pival
reacyl
benzyl
chloroform
led
diol
deprotect
differenti
oxygen
substitu
achiev
use
boc
yb
otf
lead
select
hydroxi
group
oxid
keton
use
iodoxybenzo
acid
ibx
nabh
conclud
synthesi
cet
step
dribofuranos
oy
ee
nr
ishibashi
et
al
report
asymmetr
synthesi
base
previou
construct
cet
skeleton
use
characterist
featur
eleg
radic
cascad
simultan
construct
b
c
ring
diethyl
tartrat
transform
acetonid
diol
whose
tosyl
reaction
lithium
phenylacetylid
gave
compound
scheme
bromin
acetonid
group
remov
intermedi
bromodiol
subject
bu
snhmediat
radic
cycliz
afford
cyclopentan
diol
yield
eight
step
two
hydroxyl
group
protect
subsequ
ozonolysi
afford
desir
chiral
cyclopentanon
condens
amin
presenc
ti
oipr
give
intermediari
imin
acyl
acryloyl
chlorid
afford
enamid
yield
scheme
treatment
bu
snh
presenc
azobiscyclohexanecarbonitril
acn
gener
radic
cascad
reaction
build
simultan
two
ring
b
c
select
cycliz
deliv
desir
abcd
compound
yield
deprotect
silyl
hydroxyl
group
tetrabutylammonium
fluorid
gave
diol
treatment
trifluoroacet
acid
anhydrid
dimethyl
sulfoxid
et
n
treatment
afford
compound
methyl
ultim
reduct
use
aluminum
hydrid
led
cet
ee
end
total
asymmetr
synthesi
oy
step
diethyl
dtartrat
nagasaka
et
al
propos
synthesi
cet
entcet
via
resolut
chiral
actet
spiroketon
ae
provid
c
ring
scheme
compound
use
known
procedur
develop
kuehn
alkyl
stork
enamin
cyclopentanon
methyl
acryl
gave
cyclopentanon
ester
format
vinyl
acet
nitro
group
nitrogen
atom
precursor
introduc
use
ammonium
nitrat
trifluoroacet
anhydrid
yield
nitro
compound
reduct
nitro
group
situ
lactam
allow
format
spirolactam
ae
acet
ae
r
r
afford
two
diastereoisom
easili
separ
hplc
combin
optic
puriti
check
chiral
hplc
compound
obtain
hydrolysi
respect
acet
enantiom
confirm
enantiomer
pure
two
diastereoisom
alkyl
sulfon
ester
lead
kuehn
intermedi
synthesi
cet
entcet
estim
cephalotaxu
alkaloid
ee
could
achiev
employ
kuehn
procedur
step
cyclopentanon
calcul
oy
enantiom
el
biali
et
al
recrystal
ammonium
malat
spiro
compound
ae
gave
enantiom
could
convert
unnatur
entcet
mother
liquor
malat
salt
afford
ikeda
intermedi
yield
report
protect
oxid
known
keton
transform
accord
sequenc
hplc
appli
hanaoka
protocol
would
allow
synthesi
cet
step
oy
estim
ee
piperon
stoltz
et
al
develop
formal
asymmetr
synthesi
two
enantiom
cet
first
total
synthesi
dupracin
use
spirocycl
amin
ae
first
use
synthesi
raccet
ae
scheme
introduc
cd
ring
compound
ae
coupl
chiral
nonracem
hemiacet
obtain
chemic
resolut
scheme
acid
r
ee
obtain
chemic
resolut
ephedrin
protect
prior
bromat
reduct
deliv
compound
mixtur
diastereom
mixtur
react
spirocycl
amin
ae
see
scheme
reduct
amin
condit
give
diastereom
ratio
smoothli
separ
chromatographi
diastereom
submit
separ
heck
reaction
condit
produc
benzazepin
pyrrolofus
pyridinium
salt
irradi
give
tricycl
aziridin
regioselect
ring
open
acet
acid
amin
protect
boc
protect
alcohol
acet
ester
last
deprotect
boc
group
tfa
led
meso
spirocycl
aminodiest
five
step
oy
desymmetr
enzymat
hydrolysi
electr
eel
acetyl
cholinesteras
afford
unstabl
aminomonoalcohol
rang
ee
react
acetyl
chlorid
furnish
amidoalcohol
remov
hydroxi
group
compound
transform
oxal
underw
radic
reduct
treatment
azobisisobutyronitril
aibn
nbu
snh
gener
desir
product
yield
along
isomer
homoallyl
alcohol
major
product
mori
intermedi
obtain
reduct
lialh
also
obtain
fivestep
sequenc
oy
rearrang
homoallyl
alcohol
involv
alcohol
deprotect
oxid
bunsatur
enon
format
keton
amid
reduct
formal
synthesi
could
allow
synthesi
cet
step
via
acd
intermedi
expect
oy
oy
brsm
estim
ee
medium
ee
indic
epimer
occur
transform
spirocycl
compound
acd
unit
second
approach
mariano
et
al
describ
synthesi
acd
unit
key
intermedi
describ
suga
yoshida
scheme
azaspiroalcohol
prepar
earlier
enantiomer
pure
form
use
sequenti
photocyclizationaziridin
ring
openingenzymat
desymmetr
sequenc
ee
four
step
oy
pyridinium
salt
radic
reduct
tributyltin
hydrid
aibn
mix
oxal
gave
homoallyl
ester
hydrogen
pdc
follow
hydrolysi
hcl
gener
spirocycl
alkanolamin
reaction
iodoarylacetyl
chlorid
furnish
spirocycl
amidoalcohol
transform
tosyl
tosyl
elimin
dbu
afford
unsatur
amid
reduc
aluminum
trihydrid
give
suga
yoshida
intermedi
formal
synthesi
would
give
cet
expect
ee
step
calcul
oy
alcohol
anoth
formal
synthesi
cet
report
renaud
unlik
altern
approach
see
section
scheme
access
azaspiroamid
nagasaka
intermedi
achiev
stereoselect
carboazid
sequenc
key
step
scheme
synthesi
silyl
deriv
ee
prepar
racem
cyclopentanol
conclud
part
interest
compar
target
intermedi
formal
synthes
cet
subtl
chang
structur
may
induc
differ
reactiv
oy
transform
cet
either
racem
form
ae
fig
optic
activ
one
natur
enantiom
distom
fig
addit
schemat
view
show
way
interconnect
differ
approach
side
chain
cephalotaxu
alkaloid
import
biolog
activ
correspond
ester
sinc
well
known
cet
exhibit
interest
activ
character
rel
simpl
structur
chiral
tertiari
alcohol
moieti
nevertheless
coupl
side
chain
cet
remain
import
challeng
due
steric
figur
target
intermedi
formal
synthes
ae
cephalotaxin
name
box
refer
formal
synthesi
figur
target
intermedi
formal
asymmetr
synthes
cephalotaxin
name
box
refer
formal
synthesi
side
chain
thu
appear
synthes
acid
side
chain
use
process
attain
cephalotaxu
ester
nevertheless
numer
interest
synthes
acid
side
chain
report
first
report
synthesi
cet
ester
synthesi
side
chain
part
synthes
present
chronolog
order
previou
review
seri
report
synthes
cet
ester
due
imposs
coupl
entir
side
chain
synthes
dealt
esterif
cet
precursor
aketo
acid
shown
scheme
format
aketoest
follow
introduct
acetyl
group
reformatski
reaction
although
esterificationreformatski
alkyl
sequenc
interest
proceed
well
allow
prepar
variou
ht
ht
hht
deoxyht
sequenc
also
exhibit
major
drawback
reformatski
reaction
prochir
ketoest
part
continu
gave
mixtur
two
epim
mixtur
lead
thu
loss
half
part
cet
major
inconveni
avoid
two
synthes
hht
synthesi
report
hudlicki
presenc
second
keto
group
allow
chelat
reformatski
reagent
lead
format
singl
stereom
synthesi
cheng
use
chiral
sulfinyl
ester
sinc
previou
review
seri
four
articl
deal
synthes
cet
ester
publish
first
one
robin
quit
interest
open
new
rout
alkaloid
strategi
base
esterif
cet
cyclic
precursor
side
chain
tetrahydropyran
scheme
easili
prepar
four
step
aketoest
ketoest
treat
lithium
methyl
acet
give
diester
fulli
saponifi
cycliz
formic
acid
diacid
latter
select
monoesterifi
bf
meoh
furnish
acid
ester
cet
coupl
use
dicyclohexylcarbodiimid
mix
anhydrid
method
obtain
ester
mixtur
two
epim
ratio
separ
chromatographi
author
show
highli
enantiomer
pure
hht
ee
could
obtain
larg
scale
process
also
develop
diastereoselect
sequenc
purpos
resolv
quinin
ester
eventu
coupl
cet
gave
anhydrohht
also
hydrolyz
enantiopur
hht
methodolog
use
tetrahydropyran
patent
appli
synthet
variou
analog
accord
effici
semisynthesi
describ
use
enantiopur
robin
acid
synthet
strategi
obtain
c
cet
cephalotaxu
alkaloid
alcohol
obtain
piperon
sequenc
provid
prepar
revers
phase
hplc
enantiopur
product
radiochem
puriti
chemic
puriti
oy
synthesi
deoxyht
report
gin
recent
also
effici
method
synthesi
cet
ester
synthesi
base
esterif
cyclic
acid
name
blacton
obtain
nonracem
form
effici
sequenc
scheme
start
acet
derivat
dmalic
acid
pivalaldehyd
give
dioxolanon
diastereoselect
alkyl
dioxolanon
prenyl
bromid
accomplish
deproton
lihmd
give
prenyl
dioxolanon
yield
sequenc
allow
introduct
chiral
tertiari
alcohol
complet
diastereoselect
follow
studi
seebach
tietz
see
scheme
transesterif
acet
cleavag
use
benzyl
alcohol
provid
tertiari
alcohol
cycliz
blacton
follow
hydrogenolysi
hydrogen
give
acid
activ
carboxyl
function
chlorid
allow
acyl
cet
follow
transform
deoxyht
methanolysi
homoharringtonin
homodeoxyharringtonin
djaballah
gin
cowork
extend
studi
synthes
other
cet
ester
hht
homodeoxyht
anhydroht
prepar
anhydroht
scheme
involv
intermedi
r
previou
synthesi
see
scheme
transform
correspond
methyl
ester
cycliz
tetrahydrofuran
alkoxymercur
deprotect
benzyl
ester
activ
mix
anhydrid
yamaguchi
reagent
allow
coupl
cet
give
anhydroht
excel
yield
prepar
hht
homodeoxyht
scheme
involv
synthesi
base
blacton
obtain
sequenc
mimick
synthesi
describ
scheme
crossmetathesi
provid
disubstitut
alken
yield
dimer
bislacton
also
form
cleavag
benzyl
ester
activ
carboxyl
group
yamaguchi
reagent
allow
coupl
cet
furnish
transform
methanolysi
prepar
natur
compound
hht
homodeoxyht
common
intermedi
interest
allyl
benzyl
ether
treat
h
pdc
meoh
follow
addit
acoh
last
stage
reaction
hht
isol
yield
hand
gave
homodeoxyht
yield
submit
pdc
catalyz
hydrogen
glacial
acoh
though
clearli
shown
coupl
cet
entir
side
chain
possibl
synthes
side
chain
continu
prolif
synthes
report
sinc
asymmetr
interest
due
divers
origin
includ
prepar
alreadi
describ
intermedi
synthesi
cephalotaxu
ester
could
consid
formal
synthes
natur
product
first
asymmetr
synthesi
side
chain
ester
hht
report
duma
dangelo
work
format
chiral
tertiari
alcohol
center
accomplish
highli
diastereoselect
manner
earli
stage
sequenc
synthesi
start
prepar
known
chiral
imin
scheme
subject
michael
reaction
acetoxyacrylonitril
equival
acid
side
chain
adduct
prove
stereochem
homogen
hydrolyz
without
purif
give
stabl
keton
r
r
keto
group
protect
dioxolan
potenti
aldehyd
function
directli
transform
ester
treatment
mno
meoh
presenc
nacn
ketal
ester
cleav
use
cecl
nai
soform
keto
group
convert
silylvinyl
ether
ozonolysi
gave
sensit
aldehyd
addit
memgbr
crude
aldehyd
esterif
acid
furnish
alcohol
oxid
alcohol
methylketon
follow
new
addit
memgbr
gave
tertiari
alcohol
eventu
hydrogenolysi
led
r
methyl
methyl
deriv
hht
side
chain
tietz
report
prepar
chiral
side
chain
acid
deoxyht
homodeoxyht
nordeoxyht
neoht
respect
scheme
base
seebach
procedur
alkyl
dmalic
acid
selfregener
stereogen
center
strategi
use
later
gin
prepar
cet
ester
dioxolanon
prepar
dmalic
acid
treat
two
equivat
lihmd
follow
bromoallyl
deriv
give
allyl
dioxolanon
high
yield
diastereoselect
hydrogen
pto
compound
furnish
dioxolanon
whose
acid
hydrolysi
permit
isol
side
chain
deoxyht
homodeoxyht
nordeoxyht
respect
alkyl
benzyl
bromid
sequenc
allow
obtent
side
chain
neoht
origin
approach
report
russel
et
al
three
compound
describ
studi
r
r
anhydroht
hht
side
chain
respect
r
intermedi
use
robin
synthesi
hht
see
scheme
thu
repres
formal
synthesi
hht
dioxolanon
r
obtain
three
step
resolut
oy
citric
acid
acid
function
r
select
reduc
sever
cephalotaxu
alkaloid
side
chain
prepar
royer
rapid
synthesi
fouref
step
hand
postul
epoxid
could
good
candid
esterif
cet
report
coupl
avail
diester
easili
obtain
commerci
avail
monomethyl
itacon
methyl
mandel
epoxyd
mcpba
give
diastereomer
mixtur
good
yield
flash
chromatographi
permit
isol
requir
absolut
configur
epoxid
react
variou
organocupr
give
compound
hydrogenolysi
allow
obtent
r
r
r
side
chain
deoxyht
homodeoxyht
neoht
respect
analog
r
oy
hydroxymercur
follow
spontan
cycliz
hydrogenolysi
chiral
appendag
deliv
r
side
chain
anhydroht
oy
yang
report
meisenheim
rearrang
gener
strategi
construct
chiral
tertiari
alcohol
illustr
method
synthesi
ht
hht
side
chain
shown
scheme
synthesi
began
known
nboc
ester
laspart
acid
obtain
twostep
process
gemdimethyl
group
first
instal
grignard
reaction
give
transform
lactol
ibx
oxid
concomit
cycliz
wittig
reaction
phosphoran
follow
deprotect
nbisbenzyl
amino
group
furnish
key
allylamin
meisenheim
rearrang
occur
treatment
mcpba
latter
give
hydroxylamin
compound
led
treatment
h
catalyt
pdc
via
doubl
bond
satur
neo
bond
cleavag
eventu
oxid
hht
side
chain
acid
r
obtain
whose
methyl
yield
correspond
dimethyl
ester
r
optic
rotat
indic
perfect
stereochem
outcom
rearrang
similar
process
allow
synthesi
cyclic
form
ht
side
chain
start
lthreonin
amino
alken
prepar
seven
step
meisenheim
rearrang
occur
treat
mcpba
give
sensit
hydroxylamin
six
step
need
obtain
r
cyclic
form
ht
side
chain
acid
author
patent
prepar
hht
side
chain
acid
r
methodolog
sequenc
yang
cowork
also
describ
synthesi
diacid
side
chain
deoxyht
homodeoxyht
start
lvalin
lleucin
respect
hung
et
al
recent
report
synthesi
ester
side
chain
hht
homodeoxyht
respect
use
tietz
gin
method
scheme
allyl
see
scheme
esterif
crossmetathesi
see
scheme
allyl
alcohol
allow
prepar
dioxolanon
latter
subject
differ
hydrogen
condit
give
methanolysi
r
r
side
chain
ester
hht
homodeoxyht
tietz
method
see
scheme
also
use
mac
et
al
synthesi
seri
side
chain
analog
hht
scheme
dioxolanon
diastereoselect
allyl
furnish
compound
r
r
mizorokieheck
type
reaction
variou
phenylboron
acid
deriv
follow
hydrogen
methanolysi
gave
aryl
ester
chain
analog
hht
moder
good
yield
synthesi
analog
bioactiv
natur
product
remain
broad
area
research
lead
interest
new
structur
improv
activ
case
cephalotaxu
alkaloid
exchang
ester
side
chain
appear
simplest
way
access
analog
strategi
use
describ
patent
structur
modif
cet
core
seem
difficult
also
scarc
address
give
rise
interest
compound
synthet
pathway
describ
signific
report
work
describ
r
r
scheme
synthesi
homoharringtonin
side
chain
analog
mac
cephalotaxu
alkaloid
attempt
synthes
cet
prepar
compound
pass
structur
resembl
consid
section
sinc
sever
report
synthesi
cet
analog
appear
tietz
et
al
describ
prepar
four
analog
compound
variat
size
differ
ring
b
c
polycycl
core
cet
ring
substitut
explor
author
use
strategi
develop
synthesi
natur
product
scheme
compound
variou
chain
length
ring
size
easili
prepar
step
alkyl
use
standard
n
reaction
compound
submit
pdcatalyz
tsujietrost
cycliz
give
e
f
h
scheme
synthesi
cephalotaxin
analog
tietz
satisfactori
yield
compound
g
cycliz
condit
final
heck
cycliz
requir
use
hermannebel
palladacycl
allow
prepar
compound
studi
final
compound
requir
reaction
instal
least
alcohol
function
ring
allow
coupl
side
chain
drawback
elimin
follow
studi
publish
author
furthermor
cephalotaxu
ester
analog
prepar
coupl
cet
analog
homodeoxyht
side
chain
scheme
synthesi
base
domino
reaction
give
rapid
effici
access
acd
compound
amin
cyclopentenon
ester
pdcatalyz
reaction
allow
format
tetracycl
lialh
reduct
gave
effici
access
amino
alcohol
analog
cet
compound
coupl
activ
form
side
chain
homodeoxyht
contrast
observ
nabh
reduct
scheme
synthesi
deoxyharringtonin
analog
tietz
c
gave
amidoalcohol
c
allow
coupl
imidazolid
homodeoxyht
side
chain
furnish
reduct
ester
c
analog
homodeoxyht
note
present
synthesi
racem
optic
pure
side
chain
use
lead
mixtur
two
diastereom
separ
bubnov
et
al
publish
synthesi
compound
exhibit
structur
analog
cet
ring
b
bridg
fuse
scheme
synthet
strategi
simpl
start
diallyl
n
nprotect
transform
spiropyrrolidin
ring
closur
metathesi
condens
acyl
chlorid
gave
access
transform
desir
product
heck
cycliz
type
work
pursu
author
allow
prepar
new
product
protect
lactam
deproton
use
secbuli
addit
mei
bui
phch
br
provid
diastereomer
alkyl
lactam
ratio
new
chiral
center
major
isom
configur
transform
acetonid
led
alkyl
cet
fourstep
sequenc
oy
author
report
differ
type
cet
analog
ring
chang
phenyl
naphthyl
group
scheme
use
strategi
cet
synthesi
see
scheme
nalkyl
spirolactam
l
appropri
arylethyl
deriv
b
gave
b
end
synthesi
parallel
cet
synthesi
function
group
manipul
b
led
b
spiro
compound
b
cycliz
abcd
compound
b
eventu
transform
phenyl
naphthyl
cet
analog
chandrasekhar
et
al
use
aryn
insert
methodolog
synthet
three
cet
analog
intermedi
scheme
compound
ring
chang
phenyl
dimethylphenyl
dimethoxyphenyl
ring
conclud
noteworthi
sever
analog
cet
design
synthes
coupl
side
chain
two
product
two
report
although
biolog
activ
report
treat
sodium
hydrid
yield
synthet
cet
ester
yield
compound
activ
test
analog
studi
nanomolar
ic
ngml
hht
less
potent
ic
ngml
analog
ht
drupangtonin
hht
also
synthet
convent
method
fig
work
delin
ester
group
reduc
cytotox
activ
leukem
cell
line
tabl
nevertheless
one
gave
rise
improv
activ
ester
nhexadienyl
nhexyl
nhepthyl
djaballah
gin
synthes
four
cetest
analog
benzyldehydrohht
bisnorhomodeoxyht
bisnorhomodeoxyht
blacton
deoxyht
blacton
fig
use
protocol
describ
section
scheme
exemplifi
cephalotaxu
ester
analog
dimer
cet
link
central
oxygen
chain
hydroxyl
group
ht
structur
analog
test
human
hematopoiet
solid
tumor
cell
line
tabl
compar
hht
deoxyht
homodeoxyht
anhydroht
among
activ
cephalotaxu
alkaloid
ester
hht
show
decreas
activ
factor
resist
index
ri
wherea
ester
deoxyht
homodeoxyht
benzyldehydrohht
bisnordeoxyht
much
lower
ri
respect
indic
significantli
less
sensit
multidrug
resist
mdr
tumor
cell
line
therefor
cephalotaxu
alkaloid
consid
sensit
product
one
possibl
explan
greater
suscept
hht
mdr
low
lipophil
due
structur
side
chain
make
good
substrat
efflux
pump
compound
clogp
valu
greater
gener
lead
low
suscept
mdr
ie
ir
ester
except
hht
rel
low
valu
clogp
rel
polar
reflect
suscept
mdr
ie
ir
compound
show
broad
spectrum
cytotox
activ
except
retinoblastoma
cell
line
tabl
attribut
overexpress
mdr
gene
line
lai
et
al
appli
two
patent
one
prepar
amin
hht
deriv
fig
acyl
hht
deriv
fig
compound
prepar
hht
via
saponif
methyl
ester
hht
acid
amid
variou
amin
r
r
nh
presenc
hatudipea
yield
fig
group
r
r
could
h
c
alkyl
c
alkenyl
c
alkynyl
cephalotaxu
alkaloid
c
cycloalkyl
cycloalkenyl
aryl
heteroaryl
satur
heterocycl
ring
system
etc
twentythre
hht
aza
analog
test
human
hematopoiet
solid
tumor
cell
line
tabl
compar
hht
analog
f
n
u
inact
ic
mgml
compound
activ
test
analog
studi
nanomolar
ic
ngml
hht
potent
ic
ngml
promis
analog
test
hela
cervic
esophag
cne
nasopharyng
liver
mgc
gastric
prostat
ovari
human
cancer
cell
line
tabl
howev
none
compound
activ
hht
monoacylhht
analog
diacylhht
analog
prepar
activ
hht
carboxyl
acid
anhydrid
acyl
chlorid
via
esterif
yield
fig
acyl
analog
compar
hht
test
human
hematopoiet
tabl
solid
tumor
cell
line
tabl
includ
myelogen
leukemia
resist
dox
acut
myeloid
leukemia
aml
acut
promyelocyt
leukemia
apl
jurkat
childhood
acut
lymphoblast
leukemia
cutan
tcell
lymphoma
plasma
cell
myeloma
hepatoma
lung
adenocarcinoma
exocrin
pancrea
carcinoma
breast
osteosarcoma
rko
colon
glioma
hela
cervic
esophag
cne
nasopharyng
liver
prostat
ovari
hht
tabl
compound
potent
hht
cell
line
test
respect
conclus
studi
mani
synthes
cet
publish
date
draw
number
conclus
key
point
structur
way
chemist
overcom
problem
pose
synthesi
format
b
ring
often
remain
crucial
point
build
cet
skeleton
disconnect
remain
far
studi
synthes
cycliz
reaction
use
electrophil
aromat
substitut
organometal
coupl
etc
perform
gener
good
yield
seem
suscept
cycliz
intermedi
electron
rich
aromat
ring
disconnect
also
extrem
interest
stereochem
point
view
provid
correct
rel
configur
avoid
difficult
separ
disconnect
alway
give
good
result
complet
diastereoselect
format
spiro
cd
system
also
key
point
synthes
fact
control
center
start
synthesi
greatli
simplifi
stereocontrol
strategi
enabl
enantioselect
approach
cet
asymmetr
synthesi
cd
system
subsequ
stereoinduct
center
center
center
center
facilit
product
optic
activ
cet
howev
oper
condit
use
synthesi
spiro
system
must
chosen
care
risk
racem
cet
certain
synthet
intermedi
break
bond
see
fig
convers
mori
intermedi
ae
last
least
industri
point
view
initi
merck
group
took
weinreb
racem
synthesi
improv
perform
elimin
purif
step
optic
activ
cet
natur
configur
may
obtain
resolut
racem
cephalotaxin
raccet
ae
tartar
acid
incorpor
chiral
sourc
enantioselect
synthesi
highpur
hht
use
clinic
trial
obtain
extract
nci
batch
semisynthesi
sshht
natur
cet
purifi
hplc
remov
impur
minor
diastereoisom
first
french
compani
oncopharm
sa
later
base
houston
usa
number
hht
analog
prepar
howev
monoacyl
analog
show
slight
increas
activ
again
hematopoiet
solid
caner
cell
line
main
advantag
prepar
hydrosolubl
stabl
form
figur
simplifi
diagram
protein
synthesi
show
site
homoharringtonin
hht
bind
inhibit
protein
synthesi
cytoplasm
cell
ribosom
green
bind
mrna
contain
code
translat
switch
gene
dna
differ
amino
acid
carri
transfer
rna
trna
recruit
accord
three
nuclear
base
code
ribosom
site
protein
chain
elong
includ
aminoacyl
trna
entri
proofread
peptidyl
transfer
ribosom
transloc
along
trna
chain
cartoon
right
explain
hht
inhibit
protein
synthesi
inhibit
initi
elong
step
structur
function
ribosom
gener
model
shown
differ
antibiot
includ
hht
bind
ribosom
also
demonstr
xray
high
resolut
crystal
ribosom
complex
eukaryotespecif
inhibitor
four
broadspectrum
inhibitor
saccharomyc
cerevisia
ring
system
tail
hht
particip
interact
ribosom
contribut
drug
bind
hht
interact
ribosom
stabil
hydrophob
interact
hydrogen
bond
fig
sixmemb
aromat
ring
stack
base
cytosin
haloarcula
marismortui
escherichia
coli
fill
asit
cleft
complet
fivememb
dioxolan
ring
attach
hht
bound
ribosom
surfac
area
becom
water
inaccess
tertiari
amin
hht
one
main
action
hht
induct
apoptosi
fig
hht
differ
mechan
action
tyrosin
kinas
inhibitor
class
drug
use
treatment
cml
accordingli
activ
cml
independ
mutat
state
bcrabl
cell
particular
cml
cell
contain
fusion
gene
call
gener
transloc
sequenc
cablgen
chromosom
bcr
gene
chromosom
mechan
apoptosi
induc
hht
studi
conduct
cell
line
prove
mitochondria
involv
apoptosi
induc
hht
although
hht
induc
apoptosi
mediat
mitochondria
intrins
pathway
also
induc
apoptosi
death
receptor
extrins
pathway
intrins
pathway
induc
cleav
proactiv
form
activ
one
hht
activ
apoptosi
mediat
inhibit
apoptot
inhibitor
upregul
releas
mediat
action
genet
level
instanc
apoptosi
studi
cell
line
individu
mrna
identifi
transcript
level
significantli
chang
gene
mostli
oncogen
tumor
suppressor
enzym
kinas
partial
relat
apoptosi
upregul
downregul
follow
signal
apoptosi
pathway
activ
tgfb
tumor
necrosi
factor
tnf
fa
head
protein
intrins
apoptosi
cascad
activ
hht
human
hepatoma
cell
cell
line
mutat
resist
hht
studi
demonstr
rapid
apoptosi
cell
line
treatment
hht
measur
increas
annexin
v
bind
capac
activ
cleavag
poli
adenosin
diphosph
adp
ribos
polymeras
parp
also
express
bax
upregul
cell
death
induc
hht
express
slightli
decreas
treatment
human
myelodysplast
syndrom
md
cell
line
hht
ca
transloc
endoplasm
reticulum
er
pool
cytosol
mitochondri
membran
potenti
dwm
decreas
bid
protein
transloc
er
mitochondria
ca
bid
protein
releas
er
pool
cytosol
activ
er
stressassoci
proapoptot
factor
chop
er
chaperon
bip
gene
follow
cleavag
mrna
express
level
survivin
investig
variou
hematopoiet
cell
line
relat
apoptosi
induc
hht
conclud
apoptot
effect
hht
hematopoiet
cell
line
associ
decreas
level
survivin
express
studi
apoptosi
use
sshht
cell
lack
bax
cell
line
sshht
effect
timeand
dosedepend
manner
independ
express
bax
addit
sshht
induc
apoptosi
decreas
dwm
releas
cytochrom
c
explain
decreas
myeloid
cell
level
cleavag
one
protein
govern
outer
membran
mitochondria
antiapoptot
activ
fig
hht
inhibit
telomeras
content
cell
effect
induc
apoptosi
hht
figur
main
pathway
involv
apoptosi
mechan
induc
homoharringtonin
yellow
apoptosi
factor
blue
apoptosi
intermedi
turquois
dual
role
intermedi
factor
green
apoptosi
inhibitor
intrins
apoptosi
use
transform
subfamili
growth
factorbinduc
protein
call
transform
growth
factorbeta
induc
earli
protein
gene
studi
induc
apoptosi
upregul
bax
bim
downregul
bclxl
releas
cytochrom
c
activ
apoptot
effect
hht
studi
cell
line
use
gene
chip
technolog
found
gene
upregul
downregul
found
relat
apoptosi
oncogen
tumor
suppress
sever
gene
alter
gene
express
found
tieg
vitamin
upregul
protein
one
gene
rna
bind
motif
protein
gene
vmyc
myelocytomatosi
viral
oncogen
homolog
cmyc
activ
transform
growth
factorb
tnfesign
pathway
play
import
role
apoptosi
accord
dynam
gene
express
pattern
apoptot
cell
tieg
significantli
modifi
induct
apoptosi
critic
apoptosi
signal
transmiss
chines
team
tri
identifi
differ
gene
whose
express
modifi
apoptosi
induc
hht
leukem
cell
line
demonstr
tgfa
tnf
apoptosi
signal
pathway
initi
fa
signal
pathway
overexpress
tieg
could
induc
apoptosi
kind
cell
upregul
gene
also
upregul
probabl
involv
apoptosi
signal
pathway
efficaci
hht
ponatinibresist
phposit
cell
ponatinibr
shown
decreas
protein
express
level
bcrabl
crkl
hand
cleav
parp
level
significantli
increas
hht
treatment
reduc
express
bcrabl
well
heat
shock
protein
hsp
stabil
bcrabl
protein
found
hht
reduc
express
level
antiapoptot
protein
cmyc
hht
examin
ponatinibresist
primari
phposit
cp
cml
cell
line
synthesi
bcrabl
downregul
independ
caspas
activ
hht
antagon
specif
function
specif
requir
cancer
cell
surviv
requir
normal
cell
hht
reduc
level
prooncogen
prosurviv
protein
import
protein
tumorigenesi
short
halfliv
cyclin
cmyc
demonstr
wellstudi
transgen
mice
model
emmyc
lymphoma
harbor
lesion
pten
cytotox
hht
cellgrowth
activ
investig
three
aml
cell
line
three
cml
cell
line
aml
cell
show
sensit
cml
cell
hhtinduc
cytotox
use
cell
reveal
hht
decreas
level
xlink
inhibitor
apoptosi
protein
xiap
survivin
bcell
lymphoma
homolog
domain
protein
well
dwm
cell
express
bcell
lymphomaextralarg
bclxl
antiapoptot
transmembran
protein
mitochondria
less
respons
hhtinduc
apoptosi
cell
suggest
bclxl
play
import
role
protect
hht
induc
apoptosi
addit
demonstr
leukem
cell
line
hht
inhibit
synthesi
vascular
endotheli
growth
factor
import
mediat
angiogenesi
bone
marrow
work
thu
demonstr
possibl
antiangiogen
activ
hht
studi
identifi
novel
biomark
might
contribut
variat
respons
hht
use
panel
variou
human
lymphoblastoid
cell
line
perform
genomewid
associ
analysi
appli
use
singl
nucleotid
polymorph
snp
mrna
express
data
integr
analysi
identifi
four
uniqu
snp
associ
express
area
curv
function
valid
use
sirna
knockdown
leukemia
cell
line
show
knock
gene
cell
line
significantli
alter
hht
cytotox
overexpress
contribut
im
resist
cml
line
cell
cell
line
patient
relaps
cml
establish
time
first
diagnosi
relaps
may
new
marker
im
resist
support
fact
hht
im
yield
treatment
advantag
im
alon
block
pathway
apoptosi
vari
interv
cell
line
treat
hht
studi
result
show
viabil
cell
reduc
gradual
day
day
ascend
day
day
hht
treatment
time
cleav
express
level
cell
line
increas
gradual
day
day
decreas
day
p
day
day
hht
treatment
express
level
declin
first
went
p
autophagosom
also
increas
day
hht
treatment
conclud
apoptosi
level
cell
treat
hht
increas
begin
treatment
declin
may
associ
higher
autophagi
level
late
stage
hht
treatment
recent
studi
demonstr
hht
bind
dna
intercal
mode
also
hht
bind
telomer
gquadruplex
make
good
model
drug
design
analysi
protein
express
profil
cell
line
cml
cell
line
respons
hht
treatment
show
nine
protein
downregul
four
upregul
asid
alter
apoptot
protein
protein
associ
transcript
translat
chang
oxid
stress
respons
redox
reactionerel
protein
hsp
thioredoxin
reveal
specif
protein
decreas
hht
treatment
primari
cml
cell
line
also
found
hht
effect
inhibitor
unwant
angiogenesi
potenti
use
treatment
tumor
besid
use
treatment
cml
hht
investig
type
tumor
alon
combin
drug
hht
significantli
inhibit
prolifer
human
mm
cell
line
tumor
cell
patient
relaps
refractori
mm
dosedepend
manner
apoptot
process
associ
activ
parp
effect
hht
demonstr
mm
follow
cell
line
ejm
hht
significantli
reduc
crucial
protein
involv
myeloma
cell
surviv
myeloma
cell
line
examin
also
hht
reduc
level
cflipl
activ
induc
activ
reduct
bid
follow
hhtinduc
apoptosi
appear
mediat
via
intrins
extrins
apoptosi
pathway
result
imbal
protein
may
pivot
apoptosi
hht
also
hht
treatment
result
reduc
level
bcatenin
xiap
protein
also
contribut
diseas
progress
resist
chemotherapi
mm
hht
enhanc
effect
melphalan
bortezomib
given
combin
agent
result
suggest
hht
could
constitut
attract
option
mm
treatment
abil
simultan
target
multipl
tumorpromot
molecul
hht
bortezomib
synergist
inhibit
md
cell
prolifer
induc
apoptosi
vitro
transmembran
receptor
tyrosin
kinas
kit
oncoprotein
import
therapeut
target
part
type
iii
tyrosin
kinas
mutat
receptor
give
abil
autodimer
autophosphoryl
without
activ
ligand
eventu
lead
uncontrol
cell
prolifer
resist
apoptosi
gain
function
associ
mutat
kit
receptor
play
critic
role
pathogenesi
sm
gastrointestin
stromal
tumor
gist
hypothesi
hht
inhibitor
protein
synthesi
decreas
protein
level
kit
therebi
reduc
level
phosphokit
repeal
constitut
signal
downstream
hht
effect
vitro
vivo
demonstr
effect
inhibit
tumor
growth
mice
induc
apoptosi
tumor
cell
carri
sensit
im
insensit
im
mutat
kit
addit
hht
significantli
prolong
mous
surviv
time
aggress
sm
day
instead
though
rapid
resist
hht
observ
case
potenti
activ
hht
clear
celletyp
renal
cell
carcinoma
rcc
mutant
von
hippelelindau
gene
reveal
highthroughput
simultan
screen
counterscreen
addit
hht
potenti
treatment
gefitinibresist
nonesmal
cell
lung
cancer
accord
vivo
studi
signal
oncogen
import
tumor
continu
activ
malign
phenotyp
bcrabl
fusion
protein
cml
beststudi
exampl
hht
inhibit
protein
synthesi
thu
reduc
level
bcrabl
protein
level
kinas
activ
bcrabl
directli
inhibit
im
flavopiridol
transcript
inhibitor
medianeffect
method
use
evalu
combin
flavopiridolhht
flavopiridolim
result
analysi
indic
synergist
decreas
clonogen
synergi
increas
hht
im
administ
sequenti
oppos
simultan
transfect
imresist
cell
express
mutat
bcrabl
crossresist
flavopiridol
hht
result
provid
rational
combin
inhibitor
transcript
andor
translat
specif
kinas
inhibitor
combin
hht
dox
ratiodepend
synergist
activ
strong
synerg
observ
molar
ratio
doxhht
within
doubleload
liposom
accord
studi
liposom
codeliveri
dox
hht
could
synergist
potenti
antitumor
effect
primari
aml
cell
pretreat
decitabin
expos
haa
regimen
hht
aclarubicin
cytarabin
arac
decitabin
increas
cytotox
effect
haa
regimen
enhanc
apoptosi
chemoresist
aml
cell
synergist
effect
sulforaphan
human
cml
cell
line
chemotherapi
drug
hht
arac
found
indic
clinic
potenti
combin
hht
investig
cell
line
found
synergist
mechan
relat
apoptosi
induc
downregul
survivin
tnfrelat
apoptosisinduc
ligand
trail
proapoptot
ligand
tnfa
famili
hht
repres
effici
enhanc
trailinduc
apoptosi
potenti
applic
trailbas
anticanc
combin
therapi
agonist
antitrail
receptor
antibodi
potenti
antitumor
agent
hht
found
effect
nanomolar
dose
enhanc
trailmedi
apoptosisgrowth
suppress
cotreat
trailresist
rko
cell
hht
trail
led
effect
induct
apoptosi
complet
elimin
treat
cell
hht
suppress
express
antiapoptot
protein
cflip
enhanc
trailtrigg
activ
jnk
kinas
anoth
studi
suggest
hht
replac
toxic
substanc
cycloheximid
activ
necroptosi
signal
pathway
involv
sensit
human
cancer
cell
trailinduc
necroptosi
hht
combin
antiprolif
alkyl
agent
intercal
agent
metal
coordin
complex
pyrimidin
nucleosid
purin
nucleosid
inhibitor
nucleic
acideassoci
enzym
protein
agent
affect
structur
protein
cytoplasm
enzym
treatment
host
cellular
prolif
diseas
particularli
neoplasia
matrin
combin
hht
test
prolifer
human
aml
cell
synergist
effect
apoptosi
notic
main
mechan
hht
resist
pump
remov
hht
tumor
cell
transport
call
drugefflux
pump
pglycoprotein
also
known
action
pump
intracellular
drug
level
may
remain
subleth
case
upregul
cancer
cell
may
surviv
hhtresist
cell
line
establish
promin
overexpress
may
main
caus
multidrug
resist
sshht
deriv
bypass
might
improv
treatment
efficaci
short
hairpin
rna
shrna
design
construct
transfect
leukemia
cell
line
specif
silenc
gene
resist
ht
dox
curcumin
decreas
alongsid
decreas
express
studi
indic
shrna
recombin
plasmid
could
modul
mdr
vitro
human
mdr
bcell
lymphoma
cell
line
bjabadr
found
resist
hht
daunorubicin
dnr
etoposid
mitoxantron
mtx
studi
pharmacolog
effect
hht
molecular
level
conduct
cet
hht
test
resist
mdr
cell
line
cell
line
development
therapeut
program
nation
cancer
institut
nci
bethesda
md
usa
overexpress
confer
cem
expel
hht
cell
consequ
attenu
activ
cell
threefold
increas
hht
resist
observ
though
mdr
cell
line
show
crossresist
mechan
allerg
reaction
hht
screen
identifi
potenti
allerg
factor
histamin
receptorcel
membran
chromatographi
model
appli
captur
membraneretain
compon
could
induc
activ
retent
compon
enrich
analyz
hht
recogn
separ
identifi
hht
medic
ca
flux
assay
channel
often
mediat
ca
releas
intracellular
store
express
found
hht
retain
model
increas
phosphoryl
promot
cytosol
free
ca
elev
dosedepend
manner
verifi
activ
hht
activ
provid
indic
patient
overexpress
awar
possibl
allerg
reaction
appli
hht
inject
pharmacolog
applic
chloroform
extract
aerial
part
cephalotaxu
harringtonia
l
specimen
grown
egypt
five
known
alkaloid
cet
hht
ht
isoht
deoxyht
identifi
hplceesiem
extract
test
vitro
cytotox
cell
line
result
ic
valu
mgml
dox
ic
valu
mgml
cell
line
respect
chikungunya
viru
chikv
mosquitotransmit
viru
reemerg
signific
public
health
threat
last
decad
ht
display
potent
inhibit
chikv
infect
ec
mm
minim
cytotox
ht
act
postentri
stage
chikv
replic
cycl
strongli
interfer
process
viral
protein
synthesi
cryptosporidium
parasit
caus
cryptosporidiosi
diarrheal
diseas
usual
result
fulmin
diarrhea
death
aid
patient
chronic
infect
stunt
children
librari
drug
repurpos
candid
screen
cryptosporidium
parvum
among
hht
show
promis
vitro
activ
ic
activ
mm
hht
cet
test
hepat
b
viru
hcv
use
bovin
viral
diarrhoea
viru
bvdv
surrog
hcv
activ
rel
bvdv
determin
reduct
bvdvrna
product
protect
infect
embryon
bovin
trachea
ebtr
cell
activ
hbv
investig
hbsag
releas
hbvdna
releas
hepatoblastoma
cell
infect
hbv
hht
show
high
activ
hbv
ic
mm
hbv
low
therapeut
index
cet
hht
induc
toxic
ebtr
cell
protect
effect
bvdv
contrast
abl
inhibit
hbv
product
concentr
lower
molecul
induc
cell
toxic
suggest
potenti
use
combin
therapi
hepat
b
librari
compound
screen
antivir
activ
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
select
compound
inclus
librari
depend
current
previou
fda
approv
advanc
clinic
develop
drug
welldefin
cellular
pathway
target
includ
total
compound
activ
merscov
sarscov
identifi
ec
activ
hht
merscov
nm
ht
extrem
effect
inhibit
human
retin
glial
cell
prolifer
activ
compar
antiprolif
drug
colchicin
daunomycin
ht
therefor
potenti
drug
treatment
prolif
vitreoretinopathi
pvr
inhibitori
effect
hht
cml
ball
b
cell
cell
line
evalu
vitro
show
leukem
stem
cell
kill
treatment
hht
contrast
less
leukem
stem
cell
kill
treatment
im
dasatinib
respect
hht
demonstr
activ
coronaviru
ic
rang
nm
mm
also
hht
combin
saponin
digitonin
show
activ
trypanosoma
brucei
brucei
hht
om
inn
provid
treatment
option
distinct
mechan
action
patient
achiev
optim
outcom
tki
includ
patient
mutat
recent
review
compil
clinic
trial
conduct
first
china
mixtur
hht
ht
western
countri
use
purifi
high
puriti
sshht
report
robin
oncopharm
founder
also
known
om
allow
confirm
efficaci
cml
put
first
european
medicin
agenc
ema
applic
lead
orphan
drug
statu
unit
state
stabl
sourc
hydrosolubl
omacetaxin
report
brown
chemgenex
founder
approv
clinic
applic
hht
approv
ema
tphiladelphia
chromosom
posit
cml
patient
bcrabl
kinas
domain
mutat
resist
prior
im
therapi
approv
fda
octob
treatment
cml
cp
ap
failur
two
tki
evalu
pharmacokinet
hht
sensit
hplctandem
mass
spectrometri
lcmsm
assay
quantif
omacetaxin
inact
desmethyl
dmhht
cephalotaxin
metabolit
human
plasma
urin
develop
valid
accord
latest
fda
ema
guidelin
deuter
isotop
use
intern
standard
assay
consid
suitabl
support
clinic
pharmacolog
studi
om
sinc
omacetaxin
mainli
metabol
esteras
plasma
sampl
immedi
stabil
collect
esteras
inhibitor
store
nomin
temperatur
c
valid
plasma
assay
quantifi
analyt
concentr
rang
ngml
urin
assay
rang
ngml
concentr
accuraci
within
nomin
concentr
precis
develop
method
success
appli
human
mass
balanc
studi
omacetaxin
nearli
patient
cml
earli
chronic
phase
cp
treat
im
achiev
complet
cytogenet
respons
median
followup
period
year
annual
rate
resist
progress
mortal
studi
conduct
patient
year
old
recurr
refractori
aml
patient
evalu
respons
four
patient
respond
complet
one
respond
partial
respons
rate
median
durat
roughli
day
studi
show
potenti
use
hht
pediatr
toler
toxic
two
case
cml
patient
acquir
mutat
im
treatment
one
treat
recombin
interferonalpha
ifna
patient
complet
hematolog
respons
chr
month
later
patient
treat
hht
start
mgm
subcutan
twice
daili
consecut
day
everi
month
achiev
chr
month
outcom
patient
ap
cml
receiv
treatment
im
review
compar
outcom
histor
control
patient
treat
drug
includ
hht
treatment
includ
infa
patient
hht
patient
dnr
plu
cytarabin
toxic
major
side
effect
cpcml
apcml
respect
discontinu
due
toxic
cp
patient
ap
patient
efficaci
safeti
hht
patient
apcml
previous
treat
tyrosin
kinas
inhibitor
assess
two
phase
ii
trial
patient
apcml
myeloid
blast
phase
bpcml
receiv
subcutan
sc
omacetaxin
mgm
twice
daili
day
everi
day
hematolog
responseimprov
cytogenet
respons
day
everi
day
diseas
progress
mhr
patient
apcml
patient
bpcml
histori
mutat
male
cml
patient
report
harbor
bcrabl
mutat
im
treatment
complet
disappear
treat
hht
hht
produc
good
clinic
respons
accept
toler
level
patient
cmlcp
treat
two
tki
data
analyz
two
phase
ii
clinic
trial
patient
cmlcp
median
age
analysi
year
rang
year
eight
patient
complet
respond
median
durat
studi
month
fiftysix
patient
achiev
andor
maintain
hematolog
respons
least
week
overal
surviv
month
studi
carri
cml
patient
complet
cytogen
respons
compar
immunolog
effect
lymphocyt
hht
patient
im
patient
studi
indic
effect
recent
review
discuss
use
effect
hht
treatment
intract
cml
coverag
pharmacolog
mode
action
pharmacokinet
sc
formul
demonstr
efficaci
safeti
phase
trial
hht
mgm
sc
administ
twice
daili
bid
day
everi
day
two
cycl
mode
administr
develop
earli
clinic
studi
short
intraven
iv
infus
min
use
lifethreaten
hypotens
tachycardia
observ
dose
level
mgm
stabl
aqueou
solut
inject
hht
prepar
tartar
acid
ph
around
recent
howev
site
proton
although
obviou
unambigu
seen
cet
ht
establish
xray
diffract
studi
variou
organ
salt
observ
concord
steitz
see
fig
takano
result
impli
avail
proton
ensur
biolog
activ
therefor
ht
seem
activ
via
proton
form
maximum
toler
dose
estim
mgm
provid
vial
contain
mg
hht
steril
preservativefre
white
offwhit
lyophil
singleus
solut
inject
recent
patent
hht
incorpor
phycobiliprotein
nanoparticl
hht
given
aqueou
solut
prefer
ph
also
provid
oral
proton
form
hht
patent
potenti
applic
oral
iv
dosag
form
mm
remain
incur
diseas
patient
newli
develop
highproport
polyethyleneglycol
hpeg
longcircul
liposom
lcl
load
hht
hhtlclhpeg
may
regard
promis
nanodevic
deliv
antimm
drug
hht
treatment
mm
patient
hhtlcl
freezedri
powder
significantli
improv
storag
stabil
make
hhtlcl
freezedri
powder
conveni
dilut
administr
make
drug
liposomesustain
releas
extend
circul
time
blood
improv
util
rate
medica
effect
compon
reduc
toxic
side
effect
major
metabolit
hht
cet
detect
hplc
anoth
studi
use
c
hht
detect
hplc
mass
spectrometri
ms
high
resolut
combin
offlin
radioact
determin
six
metabolit
detect
plasma
urin
fece
unchang
hht
predomin
trial
carri
combin
hht
anticanc
drug
synerg
potenti
activ
drug
improv
therapi
outcom
case
associ
drug
effici
codeliv
form
liposom
efficaci
safeti
combin
regimen
simultan
hht
ifntherapi
prove
patient
cpcml
treat
previous
either
agent
chr
rate
clinic
trial
phase
ii
carri
previous
untreat
patient
philadephiaposit
chromosom
cpcml
treatment
consist
hht
mgm
per
day
cytarabin
mgm
per
day
drug
given
togeth
via
continu
iv
infus
day
patient
achiev
chr
although
hhtcytarabin
gener
well
toler
signific
amelior
observ
patient
interferonrefractori
cml
result
nearli
high
associ
im
newli
diagnos
patient
china
patient
cml
blast
crisi
fail
prior
singleag
therapi
im
enrol
clinic
trial
investig
induct
therapi
granulocyt
colonystimul
factor
gcsf
lowdos
hht
well
standarddos
im
ghi
outcom
studi
suggest
ghi
regimen
may
overcom
diseasepoor
respons
convent
dose
im
follow
allogen
hematopoiet
stem
cell
transplant
allohsct
nineti
patient
cml
earli
cp
receiv
tripl
regimen
ifna
arac
hht
median
durat
month
therapi
patient
therapi
chang
im
patient
achiev
chr
patient
cytogenet
respons
ph
suppress
patient
treat
regimen
combin
hht
im
among
six
case
fail
eight
case
suboptim
respond
im
therapi
trial
prove
efficaci
safeti
combin
drug
aml
patient
treat
hht
arac
dnr
regimen
complet
remiss
rate
case
six
hundr
twenti
three
newli
diagnos
chines
patient
aml
treat
induct
chemotherapeut
regimen
base
idarubicin
dnr
hht
total
complet
remiss
rate
median
surviv
month
estim
surviv
year
third
year
relaps
rate
group
chines
patient
de
novo
aml
glutathion
stransferas
theta
glutathion
stransferas
mu
mutat
administ
clinic
studi
induct
therapi
patient
treat
hht
mgm
intraven
day
arac
mgm
per
day
continu
infus
day
dnr
mgm
intraven
day
regimen
second
cours
induct
therapi
appli
patient
complet
remiss
initi
cours
induct
therapi
postremiss
therapi
consist
ha
regimen
hht
arac
cours
da
regimen
dnr
arac
cours
regimen
mtx
arac
ham
arac
day
combin
mtz
mgm
iv
day
cours
overal
surviv
diseasefre
surviv
complet
remiss
patient
doubl
present
group
better
regimen
investig
explor
effect
low
dose
hht
arac
combin
gcsf
patient
relaps
refractori
aml
patient
achiev
complet
remiss
achiev
partial
remiss
overal
respons
rate
clinic
trial
combin
regiment
hht
arac
etoposid
conduct
pediatr
patient
patient
achiev
complet
remiss
within
day
one
cours
therapi
one
patient
partial
remiss
clinic
trial
gave
good
indic
combin
haa
regimen
evalu
patient
refractori
andor
relaps
aml
efficaci
toxic
patient
achiev
complet
remiss
belemen
emuls
cur
effect
treatment
refractori
relaps
aml
combin
haa
regimen
clinic
proven
compar
two
group
one
use
haa
alon
one
use
belemen
emuls
haa
total
effect
rate
belemen
emuls
plu
haa
group
howev
total
effect
rate
haa
group
sixtyseven
patient
relaps
refractori
aml
enrol
clinic
trial
receiv
follow
treatment
hht
arac
gcsf
hag
patient
treat
hag
regimen
patient
achiev
complet
remiss
partial
remiss
overal
respons
rate
one
hundr
nineti
six
untreat
de
novo
aml
patient
recruit
china
clinic
trial
use
hht
patient
treat
hht
arac
ha
base
induct
therapi
compos
three
chemotherapeut
drug
hadm
ddnr
mmtx
complet
respons
rate
case
one
hundr
seventyon
pediatr
patient
recruit
trial
receiv
regimen
includ
hht
cytarabin
dnr
median
age
year
complet
respons
obtain
case
within
day
eventfre
surviv
fourtyeight
patient
median
age
year
enrol
clinic
studi
evalu
efficaci
toxic
haa
regimen
induct
therapi
treatment
de
novo
aml
haa
regimen
welltoler
effect
induct
regimen
patient
de
novo
aml
case
report
primari
refractori
aml
treat
combin
low
dose
hht
sorafenib
salvag
treatment
therapi
success
patient
complet
remiss
nineti
elderli
patient
aml
chosen
divid
cag
lowdos
cytarabin
aclarubicin
combin
gcsf
group
case
hag
hht
arac
combin
gcsf
group
case
cag
group
case
complet
remiss
total
effici
case
complet
remiss
hag
group
total
effici
hag
group
cag
regimen
effici
hag
elderli
patient
aml
recent
clinic
studi
elderli
patient
de
novo
aml
patient
enrol
studi
treat
hht
cytarabin
combin
gcsf
hag
updat
result
show
good
overal
surviv
recent
metaanalysi
provid
overview
effect
hht
combin
regimen
treat
aml
twentyon
studi
analyz
includ
patient
pediatr
elderli
hht
given
combin
cytarabin
dnr
idarubicin
aclacinomycin
mtx
gcsf
retroanalysi
show
superior
hht
contain
regimen
aml
treatment
clearli
potenti
clinic
applic
subtyp
leukemia
consequ
differ
clinic
trial
differ
regiment
took
place
thirtyon
adult
patient
suffer
idiopath
thrombocytopen
purpura
itp
treat
lowdos
combin
chemotherapi
consist
cyclophosphamid
prednison
day
combin
vincrinstin
day
andor
azathioprin
day
andor
hht
day
day
andor
etoposid
day
output
follow
patient
complet
remiss
partial
remiss
respons
femal
patient
report
de
novo
acut
megakaryoblast
leukemia
rare
type
aml
bcrabl
rearrang
der
transloc
neg
ph
chromosom
induct
chemotherapi
patient
achiev
partial
hematolog
remiss
patient
switch
im
plu
one
cycl
cag
regimen
lowdos
cytarabin
aclarubicin
combin
gcsf
achiev
complet
remiss
diseas
recur
day
patient
eventu
die
infect
thirtyfour
myelodysplast
syndrom
patient
mdsraeb
raebt
recruit
clinic
trial
two
regimen
therapi
either
haa
regimen
idarubicin
arac
ia
regimen
suggest
haa
regimen
effect
ia
well
toler
thirtythre
elderli
patient
enrol
clinic
trial
patient
highrisk
md
mdseaml
evalu
efficaci
toxic
chg
cytarabin
hht
gcsf
induct
chemotherapi
lowdos
cytarabin
hht
gcsf
prime
elderli
patient
highrisk
md
aml
transform
md
mdse
aml
outcom
studi
overal
respons
rate
one
cours
chg
regimen
patient
achiev
complet
remiss
patient
achiev
partial
remiss
long
trial
year
patient
enrol
evalu
effect
combin
therapi
hht
plu
alltransretino
acid
atra
e
base
therapi
treatment
apl
induct
therapi
follow
three
cours
consolid
chemotherapi
year
sequenti
therapi
patient
achiev
complet
remiss
retrospect
studi
high
risk
patient
higher
risk
md
done
compar
two
treatment
combin
therapi
lowdos
chg
decitabin
complet
remiss
significantli
differ
group
decitabin
vs
chg
clinic
studi
total
patient
acut
phase
cml
invas
pulmonari
aspergillosi
ipa
treat
voriconazol
plu
lowdos
hht
im
studi
suggest
combin
could
use
firstlin
therapi
ipa
patient
cml
case
observ
group
treat
combin
control
group
treat
fluconazol
lowdos
hht
im
effect
rate
observ
group
control
group
respect
signific
differ
studi
conclud
voriconazol
lowdos
hht
im
could
use
firstlin
antifung
treatment
ipa
patient
cml
thirtythre
patient
enrol
clinic
studi
investig
effect
ha
regimen
cmlmbc
overal
improv
cytogenet
respons
patient
partial
respons
studi
conclud
effect
treatment
cell
may
one
valuabl
clinic
paramet
assess
treatment
effect
major
side
effect
myelosuppress
condit
bone
marrow
activ
decreas
result
fewer
red
blood
cell
white
blood
cell
platelet
myelosuppress
side
effect
cancer
treatment
gastrointestin
manifest
includ
diarrhea
occur
well
case
side
effect
explain
due
effect
hht
epitheli
permeabl
intestin
cell
monolay
natur
extract
cephalotaxu
sp
natur
chines
medicin
essenti
oil
c
griffithii
inhibit
prolifer
migrat
human
cervic
cancer
cell
oil
c
griffithii
needl
extract
petroleum
ether
test
effect
prolifer
cancer
cell
mtt
assay
hela
cell
line
extract
show
import
phytocompon
multipl
cellular
target
control
breast
cancer
patent
base
chines
tradit
medicin
file
contain
cephalotaxu
ingredi
combin
differ
plant
extract
use
follow
indic
treatment
phlegm
stagnat
type
osteoarthr
liver
cancer
ischem
intestin
colic
phthisi
hepat
syndrom
leukemia
traumat
bleed
consist
hookworm
diseas
ovarian
cancer
lumpresolv
agent
gastric
cancer
treatment
gastric
cancer
liver
cancer
collater
cancer
rectal
cancer
phlegm
fluidretent
lungobstruct
type
cardiac
insuffici
treat
liverdepress
qistagn
type
breast
cancer
spleenkidneyqidefici
bladder
cancer
lung
cancer
cephalotaxu
plant
prepar
inhibit
adhes
migrat
breast
cancer
colorect
cancer
prostat
cancer
lung
cancer
gastric
cancer
osteosarcoma
cancer
cell
liver
fat
tabl
patent
dermatolog
applic
report
hht
activ
inhibitor
matrix
use
reduct
prevent
wrinkl
anoth
prepar
relat
veterinari
drug
treatment
bovin
mastiti
eventu
patent
file
use
prepar
contain
hht
treatment
water
purifi
cyanobacteria
note
ad
proof
prepar
manuscript
addit
synthet
studi
review
publish
traumat
bleed
consist
hookworm
diseas
ovarian
cancer
lump
resolv
agent
gastric
cancer
gastric
cancer
liver
cancer
collater
cancer
rectal
cancer
phlegm
fluidretent
lungobstruct
type
cardiac
insuffici
liverdepress
qistagn
type
breast
cancer
spleenkidneyqidefici
bladder
cancer
lung
cancer
adhes
migrat
breast
cancer
colorect
cancer
prostat
cancer
lung
cancer
gastric
cancer
osteosarcoma
cancer
cell
liver
fat
